You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Author Index Volume 54 (2016)

The issue number is given in front of the pagination

Aarsland, D., see Bonanni, L. (4) 1649–1657

Aarsland, D., see van Steenoven, I. (1) 287–295

Abadie, C., see Gourmaud, S. (4) 1659–1670

Abbate, C., see Arosio, B. (2) 417–425

Abrahams, J.P., see Tiiman, A. (3) 971–982

Acharya, N.K., see Goldwaser, E.L. (2) 445–456

Acuña-Ayala, H., see Calderón-Garcidueñas, L. (2) 597–613

Adam, K., see Tsolaki, M. (1) 129–133

Adeli, A., see Scharre, D.W. (3) 995–1004

Adzhubei, A.A., see Morozov, A.V. (2) 763–776

Agrawal, P., see Scharre, D.W. (3) 995–1004

Aiyaz, M., see Hakobyan, S. (2) 707–716

Aldebert, J., see Chapleau, M. (3) 941–955

Allali, G., V. Garibotto and F. Assal, Parkinsonism Differentiates Idiopathic Normal Pressure Hydrocephalus from Its Mimics (1) 123–127

Allen, H.R., see Myers, C.A. (4) 1359–1364

Allison, W.T., see Leighton, P.L.A. (1) 3–29

Almeida, O.F.X., see Li, Y. (1) 135–148

Alva, N., see Ettcheto, M. (1) 233–251

Alvarez, A.R., see Estrada, L.D. (3) 1193–1205

Amadio, M., see Marchesi, N. (2) 535–547

Amaratunga, D., see Wijesinghe, P. (4) 1607–1618

Amaro Jr, E., see Grinberg, L.T. (1) 169–174

Ambrose, C.T., The Role of Capillaries in the Lesser Ailments of Old Age and in Alzheimer’s Disease and Vascular Dementia: The Potential of Pro-Therapeutic Angiogenesis (1) 31–43

Ames, D., see Connors, M.H. (1) 149–155

Amin, N.D., see Binukumar, B.K. (2) 525–533

Andersen, B.G., see Zakarias, J.K. (3) 1183–1192

Andersohn, F., see Brüuggenjürgen, B. (4) 1365–1372

Anderson, W.S., see Lozano, A.M. (2) 777–787

Andrés-Benito, P., see Aso, E. (3) 903–912

Anghinah, R., see Grinberg, L.T. (1) 169–174

Antoine, P., see El Haj, M. (2) 515–523

Anton, M., see Ordoñez-Gutierrez, L. (2) 645–656

Antuono, P.G., see Chen, G. (3) 983–993

Apostolova, I., see Ritter, K. (4) 1319–1331

Arcaro, M., see Cioffi, S.M.G. (2) 717–721

Arnold, S.E., see Roalf, D.R. (1) 325–335

Arora, A.S., see Karch, A. (4) 1385–1393

Arosio, B., M. Casati, C. Gussago, E. Ferri, C. Abbate, V. Scortichini, E. Colombo, P.D. Rossi and D. Mari, Adenosine Type A2A Receptor in Peripheral Cell from Patients with Alzheimer’s Disease, Vascular Dementia, and Idiopathic Normal Pressure Hydrocephalus: A New/Old Potential Target (2) 417–425

Asaad, W.F., see Lozano, A.M. (2) 777–787

Ashford, J.W., see Durazzo, T.C. (1) 99–107

Aso, E., P. Andrés-Benito and I. Ferrer, Delineating the Efficacy of a Cannabis-Based Medicine at Advanced Stages of Dementia in a Murine Model (3) 903–912

Aso, E., see López-González, I. (2) 471–475

Assal, F., see Allali, G. (1) 123–127

Astakhova, T.M., see Morozov, A.V. (2) 763–776

Asthana, S., see Racine, A.M. (4) 1395–1408

Auckland, L.D., see Parham, C.L. (4) 1629–1647

Audekerke, J.V., see Blockx, I. (2) 723–735

Auladell, C., see Ettcheto, M. (1) 233–251

Avila-Ramírez, J., see Calderón-Garcidueñas, L. (2) 597–613

Azqueta, A., see Bengoetxea, X. (3) 1085–1094

Baéz, S., see Santamaría-García, H. (3) 957–970

Baird, A., see Hakobyan, S. (2) 707–716

Baker, S., J.C. Polanco and J. Götz, Extracellular Vesicles Containing P301L Mutant Tau Accelerate Pathological Tau Phosphorylation and Oligomer Formation but Do Not Seed Mature Neurofibrillary Tangles in ALZ17 Mice (3) 1207–1217

Baltuch, G., see Lozano, A.M. (2) 777–787

Bannach, O., see Hülsemann, M. (1) 79–88

Bar, R., see Boehm-Cagan, A. (3) 1219–1233

Barcikowska, M., see Mandecka, M. (1) 157–168

Barczak, A., see Mandecka, M. (1) 157–168

Bard, F., see Blockx, I. (2) 723–735

Barnes, A., see Westona, P.S.J. (4) 1297–1302

Barocco, F., see Cioffi, S.M.G. (2) 717–721

Barrentine, L.W., see Shankle, W.R. (3) 1073–1084

Bartorelli, L., see Sepe-Monti, M. (3) 1235–1246

Baschieri, F., see Chiasserini, D. (1) 55–67

Bauer, C., see Klafki, H.-W. (2) 691–705

Beas-Zarate, C., see Ettcheto, M. (1) 233–251

Beckelman, B.C., S. Day, X. Zhou, M. Donohue, G.K. Gouras, E. Klann, C.D. Keene and T. Ma, Dysregulation of Elongation Factor 1A Expression is Correlated with Synaptic Plasticity Impairments in Alzheimer’s Disease (2) 669–678

Bell, J.S., see Tan, E.C.K. (4) 1425–1435

Bengoetxea, X., A. López de Cerain, A. Azqueta and M.J. Ramirez, Purported Interactions of Amyloid-b and Glucocorticoids in Cytotoxicity and Genotoxicity: Implications in Alzheimer’s Disease (3) 1085–1094

Benito-Cuesta, I., see Ordoñez-Gutierrez, L. (2) 645–656

Bergquist, J., see Musunuri, S. (4) 1671–1686

Berman, S.E., see Racine, A.M. (4) 1395–1408

Bernasconi, M.P., see Mazzeo, S. (4) 1495–1508

Berti, A., see Luccarini, I. (2) 737–750

Bertoux, M., S. Ramanan, A. Slachevsky, S. Wong, F. Henriquez, G. Musa, C. Delgado, E. Flanagan, M. Bottlaender, M. Sarazin, M. Hornberger and B. Dubois, So Close Yet So Far: Executive Contribution to Memory Processing in Behavioral Variant Frontotemporal Dementia (3) 1005–1014

Bhaskar, M., see Binukumar, B.K. (2) 525–533

Bickel, H., see Heser, K. (1) 185–199

Bickel, H., see Wolfsgruber, S. (3) 1135–1146

Bielicki, J.K., see Boehm-Cagan, A. (3) 1219–1233

Bigio, E.H., see Guo, L. (3) 1157–1167

Bilgel, M., see Racine, A.M. (4) 1395–1408

Binukumar, B.K., S.L. Pelech, C. Sutter, V. Shukla, N.D. Amin, P. Grant, M. Bhaskar, S. Skuntz, J. Steiner and H.C. Pant, Profiling of p5, a 24 Amino Acid Inhibitory Peptide Derived from the CDK5 Activator, p35 CDKR1 Against 70 Protein Kinases (2) 525–533

Biscetti, L., see Chiasserini, D. (1) 55–67

Bittner, D., see Ritter, K. (4) 1319–1331

Bix, G., see Parham, C.L. (4) 1629–1647

Bjerke, M., see Somers, C. (1) 383–395

Blanc, F., see van Steenoven, I. (1) 287–295

Blawath, S., see Middelstädt, J. (1) 253–268

Bleckwenn, M., see Heser, K. (1) 185–199

Blennow, K., see Portelius, E. (4) 1593–1605

Blennow, K., see Racine, A.M. (4) 1395–1408

Blockx, I., S. Einstein, P.-J. Guns, J.V. Audekerke, C. Guglielmetti, W. Zago, D. Roose, M. Verhoye, A. Van der Linden and F. Bard, Monitoring Blood-Brain Barrier Integrity Following Amy-loid- ι ι ι Immunotherapy Using Gadolinium-Enhanced MRI in a PDAPP Mouse Model (2) 723–735

Bodin, M., see Portelius, E. (4) 1593–1605

Boehm-Cagan, A., R. Bar, O. Liraz, J.K. Bielicki, J.O. Johansson and D.M. Michaelson, ABCA1 Agonist Reverses the ApoE4-Driven Cognitive and Brain Pathologies (3) 1219–1233

Bogucka-Kocka, A., see Ułamek-Kozioł, M. (1) 113–121

Bogucki, J., see Ułamek-Kozioł, M. (1) 113–121

Bomanji, J.B., see Westona, P.S.J. (4) 1297–1302

Bonanni, L., R. Franciotti, F. Nobili, M.G. Kramberger, J.-P. Taylor, S. Garcia-Ptacek, N.W. Falasca, F. Famà, R. Cromarty, M. Onofrj, D. Aarsland and on behalf of the E-DLB study group, EEG Markers of Dementia with Lewy Bodies: A Multicenter Cohort Study (4) 1649–1657

Bonanni, L., see van Steenoven, I. (1) 287–295

Booth, K., see Brody, M. (4) 1509–1519

Bossert, I., see Chincarini, A. (4) 1437–1457

Bottlaender, M., see Bertoux, M. (3) 1005–1014

Boundy, K., see Connors, M.H. (1) 149–155

Bourgade, K., G. Dupuis, E.H. Frost and T. Fülöp Jr., Anti-Viral Properties of Amyloid-b Peptides (3) 859–878

Boutoleau-Bretonnière, C., see Magnin, E. (4) 1459–1471

Brambati, S.M., see Chapleau, M. (3) 941–955

Brashear, H.R., see Brody, M. (4) 1509–1519

Brenner, W., see Ritter, K. (4) 1319–1331

Brettschneider, C., see Heser, K. (1) 185–199

Brettschneider, C., see Wolfsgruber, S. (3) 1135–1146

Brezovakova,V., see Zimova, I. (2) 831–843

Britton, G.B., see Villarreal, A.E. (3) 897–901

Brodaty, H., see Connors, M.H. (1) 149–155

Brodtmann, A., see Malpas, C.B. (1) 223–232

Brody, M., E. Liu, J. Di, M. Lu, R.A. Margolin, J.L. Werth, K. Booth, A. Shadman, H.R. Brashear and G. Novak, A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer’s disease (4) 1509–1519

Broich, K., see Gomm, W. (2) 801–808

Bronskill, S.E., see Jaakkimainen, R.L. (1) 337–349

Brouillette, R.M., see Myers, C.A. (4) 1359–1364

Brown, E.E., Y. Iwata, J.K. Chung, P. Gerretsen and A. Graff-Guerrero, Tau in Late-Life Depression: A Systematic Review and Meta-Analysis (2) 615–633

Brüuggenjürgen, B., F. Andersohn, J. Burkowitz, N. Ezzat, M. Gaudig and S.N. Willich, Cohort Study on Predictors of Need for Nursing Care in Alzheimer’s Disease: An Analysis of Healthcare Data (4) 1365–1372

Brzozowska, J., see Ułamek-Kozioł, M. (1) 113–121

Buchert, R., see Ritter, K. (4) 1319–1331

Budziszewska, M., see Mandecka, M. (1) 157–168

Buhl, P., see Struhal, W. (2) 657–667

Burke, A., see Lozano, A.M. (2) 777–787

Burkowitz, J., see Brüuggenjürgen, B. (4) 1365–1372

Burnysheva, K.M., see Morozov, A.V. (2) 763–776

Butt, D., see Jaakkimainen, R.L. (1) 337–349

Caffarra, P., see Cioffi, S.M.G. (2) 717–721

Cai, R., see Sun, J. (1) 175–184

Calabresi, P., see Chiasserini, D. (1) 55–67

Calderón-Garcidueñas, A., see Calderón-Garcidueñas, L. (2) 597–613

Calderón-Garcidueñas, L., J. Avila-Ramírez, A. Calderón-Garcidueñas, T. González-Heredia, H. Acuña-Ayala, C.-k. Chao, C. Thompson, R. Ruiz-Ramos, V. Cortés-González, L. Martínez-Martínez, M.A. García-Pérez, J. Reis, P.S. Mukherjee, R. Torres-Jardón and I. Lachmann, Cerebrospinal Fluid Biomarkers in Highly Exposed PM2.5 Urbanites: The Risk of Alzheimer’s and Parkinson’s Diseases in Young Mexico City Residents (2) 597–613

Calderón-Garcidueñas, L., Smoking and Cerebral Oxidative Stress and Air Pollution: A Dreadful Equation with Particulate Matter Involved and One More Powerful Reason Not to Smoke Anything! (1) 109–112

Callahan, J., see Malpas, C.B. (1) 223–232

Callas, P.W., see Cushman, M. (2) 497–503

Calvó-Perxas, L., see Turró-Garriga, O. (4) 1551–1560

Calvo-Rodríguez, M., M. García-Durillo, C. Villalobos and L. Núñez, Aging Enables Ca2+ Overload and Apoptosis Induced by Amy-loid- ι ι ι Oligomers in Rat Hippocampal Neurons: Neuroprotection by Non-Steroidal Anti-Inflammatory Drugs and R-Flurbiprofen in Aging Neurons (1) 207–221

Cam, M., see Portelius, E. (4) 1593–1605

Camins, A., see Ettcheto, M. (1) 233–251

Canudas, J., see Pérez-Grijalba, V. (2) 751–762

Carbonell, T., see Ettcheto, M. (1) 233–251

Carlsson, C.M., see Racine, A.M. (4) 1395–1408

Carmona, M., see López-González, I. (2) 471–475

Casabona, D., see Pérez-Grijalba, V. (2) 751–762

Casamenti, F., see Luccarini, I. (2) 737–750

Casati, M., see Arosio, B. (2) 417–425

Cavone, L., see Luccarini, I. (2) 737–750

Cecchetti, G., see Mazzeo, S. (4) 1495–1508

Chakravarty, M.M., see Lozano, A.M. (2) 777–787

Chamorro, D., see Estrada, L.D. (3) 1193–1205

Chang, L., see Li, Y. (1) 135–148

Chang, S.-I., see Scharre, D.W. (3) 995–1004

Chang, Y.-T., see Portelius, E. (4) 1593–1605

Chao, C.-k., see Calderón-Garcidueñas, L. (2) 597–613

Chapleau, M., J. Aldebert, M. Montembeault and S.M. Brambati, Atrophy in Alzheimer’s Disease and Semantic Dementia: An ALE Meta-Analysis of Voxel-Based Morphometry Studies (3) 941–955

Chapman, B.P., see Ren, P. (1) 69–78

Chatterjee, P., see Rai, N. (3) 1147–1155

Chen, C.L.-H., see Liu, S. (2) 585–595

Chen, G., H. Shu, G. Chen, B.D. Ward, P.G. Antuono, Z. Zhang, S.-J. Li and Alzheimer’s Disease Neuroimaging Initiative, Staging Alzheimer’s Disease Risk by Sequencing Brain Function and Structure, Cerebrospinal Fluid, and Cognition Biomarkers (3) 983–993

Chen, G., see Chen, G. (3) 983–993

Chen, J.X., see Yu, Q. (2) 679–690

Chen, K., see Wang, P. (1) 359–371

Chen, X., see Zhang, H. (3) 1095–1112

Chen, Y., see Yu, L. (1) 297–306

Cheng, B., see Li, D. (1) 89–98

Cheung, C.Y., see Liu, S. (2) 585–595

Chiasserini, D., L. Biscetti, L. Farotti, P. Eusebi, N. Salvadori, V. Lisetti,F. Baschieri, E. Chipi, G. Frattini, E. Stoops, H. Vanderstichele, P. Calabresi and L. Parnetti, Performance Evaluation of an Automated ELISA System for Alzheimer’s Disease Detection in Clinical Routine (1) 55–67

Chincarini, A., F. Sensi, L. Rei, I. Bossert, S. Morbelli, U.P. Guerra, G. Frisoni, A. Padovani, F. Nobili and for the Alzheimer’s Disease Neuroimaging Initiative, Standardized Uptake Value Ratio-Independent Evaluation of Brain Amyloidosis (4) 1437–1457

Chipi, E., see Chiasserini, D. (1) 55–67

Cho, H., see Noh, Y. (3) 1015–1026

Cho, S.-J., see Kang, J.M. (3) 879–889

Chodakowska-Z?ebrowska, M., see Mandecka, M. (1) 157–168

Choe, Y.S., see Noh, Y. (3) 1015–1026

Choo, I.H., see Seo, E.H. (2) 559–568

Choo, I.H., see Seo, E.H. (3) 933–940

Chou, M.-C., see Ho, B.-L. (1) 351–357

Christian, B.T., see Racine, A.M. (4) 1395–1408

Chu, W.C.W., see Lou, W. (1) 397–409

Chung, J.K., see Brown, E.E. (2) 615–633

Cioffi, S.M.G., D. Galimberti, F. Barocco, M. Spallazzi, C. Fenoglio, M. Serpente, M. Arcaro, S. Gardini, E. Scarpini and P. Caffarra, Non Fluent Variant of Primary Progressive Aphasia Due to the Novel GRN g.9543delA(IVS3-2delA) Mutation (2) 717–721

Clark, L.R., see Mueller, K.D. (4) 1539–1550

Clark, L.R., see Racine, A.M. (4) 1395–1408

Clarnette, R., see Connors, M.H. (1) 149–155

Collins, S., see Malpas, C.B. (1) 223–232

Colombo, E., see Arosio, B. (2) 417–425

Colombrita, C., see Marchesi, N. (2) 535–547

Comi, G., see Mazzeo, S. (4) 1495–1508

Conde-Sala, J.-L., see Turró-Garriga, O. (4) 1551–1560

Connors, M.H., D. Ames, K. Boundy, R. Clarnette, S. Kurrle, A. Mander, J. Ward, M. Woodward and H. Brodaty, Mortality in Mild Cognitive Impairment: A Longitudinal Study in Memory Clinics (1) 149–155

Corcoran, N.M., see Malpas, C.B. (1) 223–232

Correani, V., see Martire, S. (1) 307–324

Cortés-González, V., see Calderón-Garcidueñas, L. (2) 597–613

Covaci, A., see Portelius, E. (4) 1593–1605

Cras, P., see Somers, C. (1) 383–395

Crocco, E., see Curiel, R.E. (2) 793–799

Cromarty, R., see Bonanni, L. (4) 1649–1657

Cubinkova, V., see Zimova, I. (2) 831–843

Curiel, R.E., E. Crocco, M. Rosado, R. Duara, M.T. Greig, A. Raffo and D.A. Loewenstein, A Brief Computerized Paired Associate Test for the Detection of Mild Cognitive Impairment in Community-Dwelling Older Adults (2) 793–799

Curole, M.V., see Shankle, W.R. (3) 1073–1084

Cushman, M., P.W. Callas, L.A. McClure, F.W. Unverzagt, V.J. Howard, S.R. Gillett, E.L. Thacker and V.G. Wadley, N-Terminal Pro-B-Type Natriuretic Peptide and Risk of Future Cognitive Impairment in the RE-GARDS Cohort (2) 497–503

Czuczwar, S.J., see Ułamek-Kozioł, M. (1) 113–121

D’Antonio, F., see Trebbastoni, A. (3) 1039–1045

d’Erme, M., see Martire, S. (1) 307–324

da Graça M. Martin, M., see Grinberg, L.T. (1) 169–174

Das, S., see Gertje, E.C. (3) 1027–1037

Davies, P., see Mead, E. (4) 1521–1538

Davis, A.B., see Myers, C.A. (4) 1359–1364

Day, S., see Beckelman, B.C. (2) 669–678

De Beaumont, L., S. Pelleieux, L. Lamarre-Théroux, D. Dea, J. Poirier and the Alzheimer’s Disease Cooperative Study, Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer’s Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects (3) 913–922

De Deyn, P., see Portelius, E. (4) 1593–1605

De Deyn, P.-P., see Somers, C. (1) 383–395

de la Sayette, V., see Magnin, E. (4) 1459–1471

de Lena, C., see Trebbastoni, A. (3) 1039–1045

De Roeck, E., see Somers, C. (1) 383–395

De Roeck, N., see Somers, C. (1) 383–395

De Silva, K.R.D., see Wijesinghe, P. (4) 1607–1618

De Vil, B., see Somers, C. (1) 383–395

Dea, D., see De Beaumont, L. (3) 913–922

Death Preparation and Boredom Reduction as Functions of Reminiscence in Alzheimer’s Disease (2) 515–523

Delgado, C., see Bertoux, M. (3) 1005–1014

Demattei, C., see Renard, D. (4) 1291–1295

Démonet, J.-F., see Magnin, E. (4) 1459–1471

Desai, G.R., see Rai, N. (3) 1147–1155

Desmond, P., see Malpas, C.B. (1) 223–232

Dey, A.B., see Rai, N. (3) 1147–1155

Dey, S., see Rai, N. (3) 1147–1155

Di, J., see Brody, M. (4) 1509–1519

Di Lazzaro, V., see Tombini, M. (4) 1619–1627

Dickensheets, T., see Johnson, L.A. (1) 201–206

Dickeson, S.K., see Parham, C.L. (4) 1629–1647

Dickson, J., see Westona, P.S.J. (4) 1297–1302

Doblhammer, G., see Gomm, W. (2) 801–808

Dobson, R., see Hakobyan, S. (2) 707–716

Doi, T., see Makizako, H. (4) 1473–1482

Donohue, M., see Beckelman, B.C. (2) 669–678

Dovas, K., see Tsolaki, M. (1) 129–133

Dovidchenko, N.V., see Selivanova, O.M. (2) 821–830

Drake, K.E., see Lozano, A.M. (2) 777–787

Duara, R., see Curiel, R.E. (2) 793–799

Dubner, L., see Varghese, M. (2) 477–496

Dubois, B., see Bertoux, M. (3) 1005–1014

Dulcey, A.E., see Estrada, L.D. (3) 1193–1205

Dumurgier, J., see Magnin, E. (4) 1459–1471

Dupuis, G., see Bourgade, K. (3) 859–878

Durazzo, T.C., M. Korecka, J.Q. Trojanowski, M.W. Weiner, R. O’ Hara, J.W. Ashford, L.M. Shaw and for the Alzheimer’s Disease Neuroimaging Initiative, Active Cigarette Smoking in Cognitively-Normal Elders and Probable Alzheimer’s Disease is Associated with Elevated Cerebrospinal Fluid Oxidative Stress Biomarkers (1) 99–107

Durieu, E., see Portelius, E. (4) 1593–1605

Duron, E., see Magnin, E. (4) 1459–1471

Dwivedi, S., see Rai, N. (3) 1147–1155

Dzhus, U.F., see Selivanova, O.M. (2) 821–830

Edwards, M., see Johnson, L.A. (1) 201–206

Edwards, M., see Villarreal, A.E. (3) 897–901

Einstein, S., see Blockx, I. (2) 723–735

El Haj, M. and P. Antoine

El Khoury, J., see Guo, L. (3) 1157–1167

Enderle, A., see Magnin, E. (4) 1459–1471

Engelborghs, S., see Somers, C. (1) 383–395

Erlandsson, A., see Musunuri, S. (4) 1671–1686

Ernst, A., see Wolfsgruber, S. (3) 1135–1146

Erokhov, P.A., see Morozov, A.V. (2) 763–776

Eslambolchilar, P., see Jenkins, A. (3) 1169–1182

Estrada, L.D., D. Chamorro, M.J. Yañez, M. Gonzalez, N. Leal, R. von Bernhardi, A.E. Dulcey, J. Marugan, M. Ferrer, C. Soto, S. Zanlungo, N.C. Inestrosa and A.R. Alvarez, Reduction of Blood Amyloid-b Oligomers in Alzheimer’s Disease Transgenic Mice by c-Abl Kinase Inhibition (3) 1193–1205

Estrella, M., see Ritter, K. (4) 1319–1331

Ettcheto, M., D. Petrov, I. Pedrós, N. Alva, T. Carbonell, C. Beas-Zarate, M. Pallas, C. Auladell, J. Folch and A. Camins, Evaluation of Neuropathological Effects of a High-Fat Diet in a Presymptomatic Alz-heimer’s Disease Stage in APP/PS1 Mice (1) 233–251

Eusebi, P., see Chiasserini, D. (1) 55–67

Evain, S., see Magnin, E. (4) 1459–1471

Eversden, S., see Mead, E. (4) 1521–1538

Evgen’ev, M.B., see Morozov, A.V. (2) 763–776

Exley, C., see Mirzaa, A. (4) 1333–1338

Ezzat, N., see Brüuggenjürgen, B. (4) 1365–1372

Falasca, N.W., see Bonanni, L. (4) 1649–1657

Falautano, M., see Mazzeo, S. (4) 1495–1508

Famà, F., see Bonanni, L. (4) 1649–1657

Fandos, N., see Pérez-Grijalba, V. (2) 751–762

Fang, D., see Yu, Q. (2) 679–690

Fang, Y., see Li, Y. (1) 135–148

Farotti, L., see Chiasserini, D. (1) 55–67

Farr, S.A., K.E. Sandoval, M.L. Niehoff, K.A. Witt, V.B. Kumar and J.E. Morley, Peripheral Administration of GSK-3b Antisense Oligonucleotide Improves Learning and Memory in SAMP8 and Tg2576 Mouse Models of Alzheimer’s Disease (4) 1339–1348

Fenoglio, C., see Cioffi, S.M.G. (2) 717–721

Fernandez, L., see López-González, I. (2) 471–475

Fernandez-Perez, I., see Ordoñez-Gutierrez, L. (2) 645–656

Ferrer, I., see Aso, E. (3) 903–912

Ferrer, I., see López-González, I. (2) 471–475

Ferrer, M., see Estrada, L.D. (3) 1193–1205

Ferri, E., see Arosio, B. (2) 417–425

Fiebach, J.B., see Ritter, K. (4) 1319–1331

Filho, W.J., see Grinberg, L.T. (1) 169–174

Filipcik, P., see Zimova, I. (2) 831–843

Filipek-Gliszczyńska, A., see Mandecka, M. (1) 157–168

Fink, A., see Gomm, W. (2) 801–808

Fiorino, A., see Mazzeo, S. (4) 1495–1508

Fladby, T., see van Steenoven, I. (1) 287–295

Flajolet, M., see Portelius, E. (4) 1593–1605

Flanagan, E., see Bertoux, M. (3) 1005–1014

Foil, H., see Myers, C.A. (4) 1359–1364

Folch, J., see Ettcheto, M. (1) 233–251

Folkerts, A.-K., see Middelstädt, J. (1) 253–268

Fontaine, G., see Portelius, E. (4) 1593–1605

Fontana, M., see Martire, S. (1) 307–324

Foote, K.D., see Lozano, A.M. (2) 777–787

Forte, E., see Martire, S. (1) 307–324

Fosdick, L., see Lozano, A.M. (2) 777–787

Fox, N.C., see Westona, P.S.J. (4) 1297–1302

Foxe, D., see Midorikawa, A. (2) 549–558

Franciotti, R., see Bonanni, L. (4) 1649–1657

Frattini, G., see Chiasserini, D. (1) 55–67

Fried, I., Brain Stimulation in Alzheimer’s Disease (2) 789–791

Frisoni, G., see Chincarini, A. (4) 1437–1457

Fritz, N., see Scharre, D.W. (3) 995–1004

Frost, E.H., see Bourgade, K. (3) 859–878

Fu, Y.H., J.-H.T. Hsiao, G. Paxinos, G.M. Halliday and W.S. Kim, ABCA7 Mediates Phagocytic Clearance of Amy-loid- ι ι ι in the Brain (2)


Fuchs, A., see Heser, K. (1) 185–199

Fuchs, A., see Wolfsgruber, S. (3) 1135–1146

Fülöp Jr., T., see Bourgade, K. (3) 859–878

Funahashi, Y., see Yoshino, Y. (4) 1349–1357

Furmaga-Jabłońska, W., see Ułamek-Kozioł, M. (1) 113–121

Fuso, A., see Martire, S. (1) 307–324

Gabelle, A., see Magnin, E. (4) 1459–1471

Gabelle, A., see Renard, D. (4) 1291–1295

Gable, S., see Levy, B. (4) 1259–1272

Gabryelewicz, T., see Mandecka, M. (1) 157–168

Gago, M., see Lima, S. (3) 1113–1121

Galimberti, D., see Cioffi, S.M.G. (2) 717–721

Galons, H., see Portelius, E. (4) 1593–1605

Galzitskaya, O.V., see Selivanova, O.M. (2) 821–830

Gamboa, A., see Johnson, L.A. (1) 201–206

Gao, X., see Li, Y. (1) 135–148

Garbis, S.D., see Portelius, E. (4) 1593–1605

García, A., see Santamaría-García, H. (3) 957–970

García-Durillo, M., see Calvo-Rodríguez, M. (1) 207–221

García-Pérez, M.A., see Calderón-Garcidueñas, L. (2) 597–613

Garcia-Ptacek, S., see Bonanni, L. (4) 1649–1657

Gardini, S., see Cioffi, S.M.G. (2) 717–721

Garibotto, V., see Allali, G. (1) 123–127

Garre-Olmo, J., see Turró-Garriga, O. (4) 1551–1560

Garrett, C., see Lima, S. (3) 1113–1121

Gascón-Bayarri, J., see Turró-Garriga, O. (4) 1551–1560

Gasse, C., see Stevnsborg, L. (2) 505–514

Gasse, C., see Zakarias, J.K. (3) 1183–1192

Gaudig, M., see Brüuggenjürgen, B. (4) 1365–1372

Genc, S., see Malpas, C.B. (1) 223–232

Georgiadis, K., see Tsolaki, M. (1) 129–133

Gerretsen, P., see Brown, E.E. (2) 615–633

Gertje, E.C., J. Pluta, S. Das, L. Mancuso, D. Kliot, P. Yushkevich and D. Wolk, Clinical Application of Automatic Segmentation of Medial Temporal Lobe Subregions in Prodromal and Dementia-Level Alzheimer’s Disease (3) 1027–1037

Geula, C., see Guo, L. (3) 1157–1167

Giacobbe, P., see Lozano, A.M. (2) 777–787

Giannakopoulos, P., see Zhang, H. (3) 1095–1112

Gibson, Y., see Mead, E. (4) 1521–1538

Gil-Kulik, P., see Ułamek-Kozioł, M. (1) 113–121

Gill, D.P., see Heath, M. (3) 923–931

Gillett, S.R., see Cushman, M. (2) 497–503

Giubilei, F., see Sepe-Monti, M. (3) 1235–1246

Glyakina, A.V., see Selivanova, O.M. (2) 821–830

Godsey, G., see Goldwaser, E.L. (2) 445–456

Goldwaser, E.L., N.K. Acharya, A. Sarkar, G. Godsey and R.G. Nagele, Breakdown of the Cerebrovasculature and Blood-Brain Barrier: A Mechanistic Link Between Diabetes Mellitus and Alzheimer’s Disease (2) 445–456

Gomm, W., K. von Holt, F. Thomé, K. Broich, W. Maier, K. Weckbecker, A. Fink, G. Doblhammer and B. Haenisch, Regular Benzodiazepine and Z-Substance Use and Risk of Dementia: An Analysis of German Claims Data (2) 801–808

Gonzalez, M., see Estrada, L.D. (3) 1193–1205

González-Heredia, T., see Calderón-Garcidueñas, L. (2) 597–613

Goodson, R., see Mead, E. (4) 1521–1538

Goossens, J., see Somers, C. (1) 383–395

Gorrie, C., see Wijesinghe, P. (4) 1607–1618

Götz, J., see Baker, S. (3) 1207–1217

Gouras, G.K., see Beckelman, B.C. (2) 669–678

Gourmaud, S., F. Mouton-Liger, C. Abadie, E.F. Meurs, C. Paquet and J. Hugon, Dual Kinase Inhibition Affords Extended in vitro Neuroprotection in Amyloid-b Toxicity (4) 1659–1670

Gövercin, M., see Ritter, K. (4) 1319–1331

Govoni, S., see Marchesi, N. (2) 535–547

Graff-Guerrero, A., see Brown, E.E. (2) 615–633

Grajales, S., see Villarreal, A.E. (3) 897–901

Grant, P., see Binukumar, B.K. (2) 525–533

Gräslund, A., see Tiiman, A. (3) 971–982

Green, D., see Jaakkimainen, R.L. (1) 337–349

Greenway, F.L., see Myers, C.A. (4) 1359–1364

Gregory, M.A., see Heath, M. (3) 923–931

Greig, M.T., see Curiel, R.E. (2) 793–799

Grigorashvili, E.I., see Selivanova, O.M. (2) 821–830

Grinberg, L.T., R. Anghinah, C.F. Nascimento, E. Amaro Jr, R.P. Leite, M. da Graça M. Martin, M.S. Naslavsky, L.T. Takada, W.J. Filho, C.A. Pasqualucci and R. Nitrini, Chronic Traumatic Encephalopathy Presenting as Alzheimer’s Disease in a Retired Soccer Player (1) 169–174

Griswold-Prenner, I., see Parham, C.L. (4) 1629–1647

Guerra, U.P., see Chincarini, A. (4) 1437–1457

Guglielmetti, C., see Blockx, I. (2) 723–735

Guns, P.-J., see Blockx, I. (2) 723–735

Guo, L., A. Rezvanian, L. Kukreja, R. Hoveydai, E.H. Bigio, M.-M. Mesulam, J. El Khoury and C. Geula, Postmortem Adult Human Microglia Proliferate in Culture to High Passage and Maintain Their Response to Amyloid-b (3) 1157–1167

Guo, X., see Wang, P. (1) 359–371

Gussago, C., see Arosio, B. (2) 417–425

Haenisch, B., see Gomm, W. (2) 801–808

Hafermann, H., see Klafki, H.-W. (2) 691–705

Häggmark-Månberg, A., see Musunuri, S. (4) 1671–1686

Hakobyan, S., K. Harding, M. Aiyaz, A. Hye, R. Dobson, A. Baird, B. Liu, C.L. Harris, S. Lovestone and B.P. Morgan, Complement Biomarkers as Predictors of Disease Progression in Alzheimer’s Disease (2) 707–716

Hall, J., see Johnson, L.A. (1) 201–206

Haller, S., see Zhang, H. (3) 1095–1112

Halliday, G.M., see Fu, Y.H. (2) 569–584

Hamilton, L., see Mead, E. (4) 1521–1538

Hampel, H., see Ritter, K. (4) 1319–1331

Hannequin, D., see Magnin, E. (4) 1459–1471

Hara, H., F. Ono, S. Nakamura, S. Matsumoto, H. Jin, N. Hattori and T. Tabira, An Oral Ab Vaccine Using a Recombinant Adeno-Associated Virus Vector in Aged Monkeys: Reduction in Plaque Amyloid and Increase in Ab Oligomers (3) 1047–1059

Hara, J., see Shankle, W.R. (3) 1073–1084

Harding, K., see Hakobyan, S. (2) 707–716

Harris, C.L., see Hakobyan, S. (2) 707–716

Hata, S., see Portelius, E. (4) 1593–1605

Hattori, N., see Hara, H. (3) 1047–1059

Haussmann, U., see Klafki, H.-W. (2) 691–705

Haynes, J.-D., see Ritter, K. (4) 1319–1331

Heath, M., J. Weiler, M.A. Gregory, D.P. Gill and R.J. Petrella, A Six-Month Cognitive-Motor and Aerobic Exercise Program Improves Executive Function in Persons with an Objective Cognitive Impairment: A Pilot Investigation Using the Antisaccade Task (3) 923–931

Heikkilä, K., see Iso-Markku, P. (4) 1303–1317

Hemachandra Reddy, P., see Vijayan, M. (2) 427–443

Henriquez, F., see Bertoux, M. (3) 1005–1014

Hermann, B., see Mueller, K.D. (4) 1539–1550

Herrera, J.L., see Ordoñez-Gutierrez, L. (2) 645–656

Herrmann, N., see Jaakkimainen, R.L. (1) 337–349

Herrmann, N., see Rosenberg, P.B. (1) 373–381

Herrmann, Y., see Hülsemann, M. (1) 79–88

Heser, K., M. Bleckwenn, B. Wiese, S. Mamone, S.G. Riedel-Heller, J. Stein, D. Lühmann, T. Posselt, A. Fuchs, M. Pentzek, S. Weyerer, J. Werle, D. Weeg, H. Bickel, C. Brettschneider, H.-H. König, W. Maier, M. Scherer and M. Wagner for the AgeCoDe Study Group, Late-Life Depressive Symptoms and Lifetime History of Major Depression: Cognitive Deficits are Largely Due to Incipient Dementia rather than Depression (1) 185–199

Hicks, R.J., see Malpas, C.B. (1) 223–232

Hilal, S., see Liu, S. (2) 585–595

Hirtz, C., see Renard, D. (4) 1291–1295

Ho, B.-L., Y.-H. Kao, M.-C. Chou and Y.-H. Yang, Cerebral White Matter Changes on Therapeutic Response to Rivastigmine in Alzheimer’s Disease (1) 351–357

Ho, L., see Varghese, M. (2) 477–496

Hodges, J.R., see Midorikawa, A. (2) 549–558

Honda, K., Cerebral Arterial Occlusion Did Not Promote the Prevalence of Cerebral Amyloid Angiopathy (1) 269–274

Hong, X., see Wang, H. (1) 275–286

Hong, Y., see Yu, L. (1) 297–306

Hornberger, M., see Bertoux, M. (3) 1005–1014

Hotta, R., see Makizako, H. (4) 1473–1482

Hovens, C.M., see Malpas, C.B. (1) 223–232

Hoveydai, R., see Guo, L. (3) 1157–1167

Howard, V.J., see Cushman, M. (2) 497–503

Hromadka, T., see Zimova, I. (2) 831–843

Hsiao, J.-H.T., see Fu, Y.H. (2) 569–584

Hu, B., see Wang, P. (1) 359–371

Huang, P., see Qiu, T. (4) 1483–1493

Huang, R., see Sun, J. (1) 175–184

Huang, Y., see Li, D. (1) 89–98

Huemer, M., see Struhal, W. (2) 657–667

Hugon, J., see Gourmaud, S. (4) 1659–1670

Hugon, J., see Magnin, E. (4) 1459–1471

Hulathduwa, S., see Wijesinghe, P. (4) 1607–1618

Hülsemann, M., C. Zafiu, K. Kühbach, N. Lühmann, Y. Herrmann, L. Peters, C. Linnartz, J. Willbold, K. Kravchenko, A. Kulawik, S. Willbold, O. Bannach and D. Willbold, Biofunctionalized Silica Nanoparticles: Standards in Amy-loid- ι ι ι Oligomer-Based Diagnosis of Alzheimer’s Disease (1) 79–88

Hutton, M., see Mead, E. (4) 1521–1538

Hye, A., see Hakobyan, S. (2) 707–716

Ibañez, A., see Santamaría-García, H. (3) 957–970

Iga, J.-i., see Yoshino, Y. (4) 1349–1357

Inestrosa, N.C., see Estrada, L.D. (3) 1193–1205

Ingelsson, M., see Musunuri, S. (4) 1671–1686

Inghilleri, M., see Trebbastoni, A. (3) 1039–1045

Insardá, P., see Tombini, M. (4) 1619–1627

Insua, D., see Pérez-Grijalba, V. (2) 751–762

Iso-Markku, P., K. Waller, E. Vuoksimaa, K. Heikkilä, J. Rinne, J. Kaprio and U.M. Kujala, Midlife Physical Activity and Cognition Later in Life: A Prospective Twin Study (4) 1303–1317

Itzhaki, R.F., Herpes and Alzheimer’s Disease: Subversion in the Central Nervous System and How It Might Be Halted (4) 1273–1281

Ivanov, A.S., see Khmeleva, S.A. (2) 809–819

Ivers, N., see Jaakkimainen, R.L. (1) 337–349

Iwata, N., see Matsunaga, S. (2) 635–643

Iwata, Y., see Brown, E.E. (2) 615–633

Jaakkimainen, R.L., S.E. Bronskill, M.C. Tierney, N. Herrmann, D. Green, J. Young, N. Ivers, D. Butt, J. Widdifield and K. Tu, Identification of Physician-Diagnosed Alzheimer’s Disease and Related Dementias in Population-Based Administrative Data: A Validation Study Using Family Physicians’ Electronic Medical Records (1) 337–349

Jabłoński, M., see Ułamek-Kozioł, M. (1) 113–121

Jadhav, S., see Zimova, I. (2) 831–843

Jager, A., see Magnin, E. (4) 1459–1471

Jakobsen, S., see Zakarias, J.K. (3) 1183–1192

Januszewski, S., see Ułamek-Kozioł, M. (1) 113–121

Jarvet, J., see Tiiman, A. (3) 971–982

Jedynak, B., see Racine, A.M. (4) 1395–1408

Jenkins, A., S. Lindsay, P. Eslambolchilar, I.M. Thornton and A. Tales, Administering Cognitive Tests Through Touch Screen Tablet Devices: Potential Issues (3) 1169–1182

Jensen-Dahm, C., see Stevnsborg, L. (2) 505–514

Jensen-Dahm, C., see Zakarias, J.K. (3) 1183–1192

Jeon, S., see Noh, Y. (3) 1015–1026

Jessen, F., see Wolfsgruber, S. (3) 1135–1146

Jin, H., see Hara, H. (3) 1047–1059

Johansson, J.O., see Boehm-Cagan, A. (3) 1219–1233

John, B., see Trebbastoni, A. (3) 1039–1045

Johnson, L.A., A. Gamboa, R. Vintimilla, M. Edwards, J. Hall, B. Weiser, M. Yadav, T. Dickensheets and S.E. O’Bryant, A Depressive Endophenotype for Predicting Cognitive Decline among Mexican American Adults and Elders (1) 201–206

Johnson, S.C., see Mueller, K.D. (4) 1539–1550

Johnson, S.C., see Racine, A.M. (4) 1395–1408

Johnson, W.D., see Myers, C.A. (4) 1359–1364

Jones, S., see Mead, E. (4) 1521–1538

Kalbe, E., see Middelstädt, J. (1) 253–268

Kang, J.M., B.K. Yeon, S.-J. Cho and Y.-H. Suh, Stem Cell Therapy for Alzheimer’s Disease: A Review of Recent Clinical Trials (3) 879–889

Kang, S.-H., see Seo, E.H. (2) 559–568

Kao, Y.-H., see Ho, B.-L. (1) 351–357

Kaprio, J., see Iso-Markku, P. (4) 1303–1317

Karakostas, A., see Lazarou, I. (4) 1561–1591

Karakostas, A., see Tsolaki, M. (1) 129–133

Karathanasi, E., see Tsolaki, M. (1) 129–133

Karch, A., F. Llorens, M. Schmitz, A.S. Arora, S. Zafar, P. Lange, C. Schmidt and I. Zerr, Stratification by Genetic and Demographic Characteristics Improves Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers in Rapidly Progressive Dementia (4) 1385–1393

Karg, F., see Portelius, E. (4) 1593–1605

Karlström, A.E., see Tiiman, A. (3) 971–982

Karpov, V.L., see Morozov, A.V. (2) 763–776

Kataki, M., see Scharre, D.W. (3) 995–1004

Kayani, I., see Westona, P.S.J. (4) 1297–1302

Keene, C.D., see Beckelman, B.C. (2) 669–678

Kegelmeyer, D., see Scharre, D.W. (3) 995–1004

Keller, J.N., see Myers, C.A. (4) 1359–1364

Kestoras, D., see Mead, E. (4) 1521–1538

Khaiboullina, S.F., see Mukhamedyarov, M.A. (4) 1373–1383

Khmeleva, S.A., S.P. Radko, S.A. Kozin, Y.Y. Kiseleva, Y.V. Mezentsev, V.A. Mitkevich, L.K. Kurbatov, A.S. Ivanov and A.A. Makarov, Zinc-Mediated Binding of Nucleic Acids to Amy-loid- ι ι ι Aggregates: Role of Histidine Residues (2) 809–819

Khoonsari, P.E., see Musunuri, S. (4) 1671–1686

Kim, G.H., see Noh, Y. (3) 1015–1026

Kim, H., see Seo, E.H. (3) 933–940

Kim, H.J., see Noh, Y. (3) 1015–1026

Kim, J.-H., see Noh, Y. (3) 1015–1026

Kim, J.S., see Noh, Y. (3) 1015–1026

Kim, M., see Zhang, H. (3) 1095–1112

Kim, S.H., see Seo, E.H. (2) 559–568

Kim, W.S., see Fu, Y.H. (2) 569–584

Kindy, M.S., see Taheri, S. (3) 1061–1072

King, A., see Mirzaa, A. (4) 1333–1338

Kiseleva, Y.Y., see Khmeleva, S.A. (2) 809–819

Kishi, T., see Matsunaga, S. (2) 635–643

Kiyasov, A.P., see Mukhamedyarov, M.A. (4) 1373–1383

Klafki, H.-W., H. Hafermann, C. Bauer, U. Haussmann, I. Kraus, J. Schuchhardt, S. Muck, N. Scherbaum and J. Wiltfang, Validation of a Commercial Chemiluminescence Immunoassay for the Simultaneous Measurement of Three Different Amy-loid- ι ι ι Peptides in Human Cerebrospinal Fluid and Application to a Clinical Cohort (2) 691–705

Klann, E., see Beckelman, B.C. (2) 669–678

Kleineidam, L., see Wolfsgruber, S. (3) 1135–1146

Klimova, B., see Maresova, P. (3) 1123–1133

Kliot, D., see Gertje, E.C. (3) 1027–1037

Kloos, A., see Scharre, D.W. (3) 995–1004

Koch, P., see Portelius, E. (4) 1593–1605

Kocki, J., see Ułamek-Kozioł, M. (1) 113–121

Kompatsiaris, I., see Lazarou, I. (4) 1561–1591

Kompatsiaris, I., see Tsolaki, M. (1) 129–133

König, H.-H., see Heser, K. (1) 185–199

König, H.-H., see Wolfsgruber, S. (3) 1135–1146

Korecka, M., see Durazzo, T.C. (1) 99–107

Koscik, R.L., see Mueller, K.D. (4) 1539–1550

Koscik, R.L., see Racine, A.M. (4) 1395–1408

Kostyk, S.K., see Scharre, D.W. (3) 995–1004

Kozin, S.A., see Khmeleva, S.A. (2) 809–819

Kramberger, M.G., see Bonanni, L. (4) 1649–1657

Kramberger, M.G., see van Steenoven, I. (1) 287–295

Kraus, I., see Klafki, H.-W. (2) 691–705

Kravchenko, K., see Hülsemann, M. (1) 79–88

Ksie?z?ak-Reding, H., see Varghese, M. (2) 477–496

Kuca, K., see Maresova, P. (3) 1123–1133

Kühbach, K., see Hülsemann, M. (1) 79–88

Kujala, U.M., see Iso-Markku, P. (4) 1303–1317

Kukreja, L., see Guo, L. (3) 1157–1167

Kulawik, A., see Hülsemann, M. (1) 79–88

Kulikova, A.A., see Morozov, A.V. (2) 763–776

Kultima, K., see Musunuri, S. (4) 1671–1686

Kumar, R., see Rai, N. (3) 1147–1155

Kumar, V.B., see Farr, S.A. (4) 1339–1348

Kumara, K.S., see Wijesinghe, P. (4) 1607–1618

Kurbatov, L.K., see Khmeleva, S.A. (2) 809–819

Kurrle, S., see Connors, M.H. (1) 149–155

Kuruppu, S., N.W. Rajapakse, A.J. Spicer, H.C. Parkington and A.I. Smith, Stimulating the Activity of Amyloid-Beta Degrading Enzymes: A Novel Approach for the Therapeutic Manipulation of Amyloid-Beta Levels (3) 891–895

Lachmann, I., see Calderón-Garcidueñas, L. (2) 597–613

Lacosta, A.M., see Pérez-Grijalba, V. (2) 751–762

Lahrmann, H., see Struhal, W. (2) 657–667

Lamarre-Théroux, L., see De Beaumont, L. (3) 913–922

Lanctôt, K.L., see Rosenberg, P.B. (1) 373–381

Landin-Romero, R., see Midorikawa, A. (2) 549–558

Lange, C., see Ritter, K. (4) 1319–1331

Lange, P., see Karch, A. (4) 1385–1393

Lannfelt, L., see Musunuri, S. (4) 1671–1686

Lapucci, A., see Luccarini, I. (2) 737–750

LaRue, A., see Mueller, K.D. (4) 1539–1550

Lazarou, I., A. Karakostas, T.G. Stavropoulos, T. Tsompanidis, G. Meditskos, I. Kompatsiaris and M. Tsolaki, A Novel and Intelligent Home Monitoring System for Care Support of Elders with Cognitive Impairment (4) 1561–1591

Lazarou, I., see Tsolaki, M. (1) 129–133

Leal, N., see Estrada, L.D. (3) 1193–1205

Lee, J.-H., see Noh, Y. (3) 1015–1026

Lee, J.M., see Noh, Y. (3) 1015–1026

Lee, J.Y., see Portelius, E. (4) 1593–1605

Lee, K.-H., see Noh, Y. (3) 1015–1026

Lee, K.H., see Seo, E.H. (3) 933–940

Lehmann, S., see Renard, D. (4) 1291–1295

Leighton, P.L.A., and W.T. Allison, Protein Misfolding in Prion and Prion-Like Diseases: Reconsidering a Required Role for Protein Loss-of-Function (1) 3–29

Leite, R.P., see Grinberg, L.T. (1) 169–174

Lemstra, A.W., see van Steenoven, I. (1) 287–295

Leoutsakos, J.-M., see Lozano, A.M. (2) 777–787

Leuxe, C., see Portelius, E. (4) 1593–1605

Levy, B., E. Tsoy and S. Gable, Developing Cognitive Markers of Alzheimer’s Disease for Primary Care: Implications for Behavioral and Global Prevention (4) 1259–1272

Leyton, C.E., see Midorikawa, A. (2) 549–558

Li, D., Y. Huang, B. Cheng, J. Su, W.-X. Zhou and Y.-X. Zhang, Streptozotocin Induces Mild Cognitive Impairment at Appropriate Doses in Mice as Determined by Long-Term Potentiation and the Morris Water Maze (1) 89–98

Li, G., see Zhang, H. (3) 1095–1112

Li, H., see Li, Y. (1) 135–148

Li, S., see Wang, H. (1) 275–286

Li, S.-J., see Chen, G. (3) 983–993

Li, Y., L. Chang, Y. Song, X. Gao, F. Roselli, J. Liu, W. Zhou, Y. Fang, W. Ling, H. Li, O.F.X. Almeida and Y. Wu, Astrocytic GluN2A and GluN2B Oppose the Synaptotoxic Effects of Amy-loid- ι ι ι 1-40 in Hippocampal Cells (1) 135–148

Liao, W., see Yuan, B. (4) 1409–1423

Lima, L.M., see Mukhamedyarov, M.A. (4) 1373–1383

Lima, S., M. Gago, C. Garrett and M.G. Pereira, Predictors and Moderators of Quality of Life in Alzheimer’s Disease Patients (3) 1113–1121

Lin, F., see Ren, P. (1) 69–78

Linder, S., see Scharre, D.W. (3) 995–1004

Lindgren, J., see Tiiman, A. (3) 971–982

Lindsay, S., see Jenkins, A. (3) 1169–1182

Ling, W., see Li, Y. (1) 135–148

Linnartz, C., see Hülsemann, M. (1) 79–88

Liraz, O., see Boehm-Cagan, A. (3) 1219–1233

Lisetti, V., see Chiasserini, D. (1) 55–67

Liu, B., see Hakobyan, S. (2) 707–716

Liu, D., see Yuan, B. (4) 1409–1423

Liu, E., see Brody, M. (4) 1509–1519

Liu, J., see Li, Y. (1) 135–148

Liu, S., Y.-T. Ong, S. Hilal, Y.M. Loke, T.Y. Wong, C.L.-H. Chen, C.Y. Cheung and J. Zhou, The Association Between Retinal Neuronal Layer and Brain Structure is Disrupted in Patients with Cognitive Impairment and Alzheimer’s Disease (2) 585–595

Llorens, F., see Karch, A. (4) 1385–1393

Lo, R.Y., see Ren, P. (1) 69–78

Loewenstein, D.A., see Curiel, R.E. (2) 793–799

Loke, Y.M., see Liu, S. (2) 585–595

Lombardi, V.C., see Mukhamedyarov, M.A. (4) 1373–1383

Londos, E., see van Steenoven, I. (1) 287–295

López de Cerain, A., see Bengoetxea, X. (3) 1085–1094

López, L., see Villarreal, A.E. (3) 897–901

López-González, I., A. Palmeira, E. Aso, M. Carmona, L. Fernandez and I. Ferrer, FOXP2 Expression in Frontotemporal Lobar Degeneration-Tau (2) 471–475

Lou, W., L. Shi, A. Wong, W.C.W. Chu, V.C.T. Mok and D. Wang, Changes of Cerebral Perfusion and Functional Brain Network Organization in Patients with Mild Cognitive Impairment (1) 397–409

Lovestone, S., see Hakobyan, S. (2) 707–716

Lozano, A.M., L. Fosdick, M.M. Chakravarty,

J.-M. Leoutsakos, C. Munro, E. Oh, K.E. Drake, C.H. Lyman, P.B. Rosenberg, W.S. Anderson, D.F. Tang-Wai, J.C. Pendergrass, S. Salloway, W.F. Asaad, F.A. Ponce, A. Burke, M. Sabbagh, D.A. Wolk, G. Baltuch, M.S. Okun, K.D. Foote, M.P. McAndrews, P. Giacobbe, S.D. Targum, C.G. Lyketsos and G.S. Smith, A Phase II Study of Fornix Deep Brain Stimulation in Mild Alzheimer’s Disease (2) 777–787

Lu, C.Y., see Tan, E.C.K. (4) 1425–1435

Lu, M., see Brody, M. (4) 1509–1519

Luccarini, I., D. Pantano, P. Nardiello, L. Cavone, A. Lapucci, C. Miceli, C. Nediani, A. Berti, M. Stefani and F. Casamenti, The Polyphenol Oleuropein Aglycone Modulates the PARP1-SIRT1 Interplay: An In Vitro and In Vivo Study (2) 737–750

Luck, T., see Wolfsgruber, S. (3) 1135–1146

Lühmann, D., see Heser, K. (1) 185–199

Lühmann, D., see Wolfsgruber, S. (3) 1135–1146

Lühmann, N., see Hülsemann, M. (1) 79–88

Lunn, M.P., see Westona, P.S.J. (4) 1297–1302

Luo, J., see Tiiman, A. (3) 971–982

Luo, X., see Qiu, T. (4) 1483–1493

Luyckx, J., see Somers, C. (1) 383–395

Lyketsos, C.G., see Lozano, A.M. (2) 777–787

Lyman, C.H., see Lozano, A.M. (2) 777–787

Ma, T., see Beckelman, B.C. (2) 669–678

Mabondzo, A., see Portelius, E. (4) 1593–1605

Macfarlane, S., see Malpas, C.B. (1) 223–232

Magnani, G., see Mazzeo, S. (4) 1495–1508

Magnin, E., J.-F. Démonet, D. Wallon, J. Dumurgier, A.-C. Troussière, A. Jager, E. Duron, A. Gabelle, V. de la Sayette, L. Volpe-Gillot, G. Tio, S. Evain, C. Boutoleau-Bretonnière, A. Enderle, F. Mouton-Liger, P. Robert, D. Hannequin, F. Pasquier, J. Hugon, C. Paquet and on behalf of ePLM collaborators, Primary Progressive Aphasia in the Network of French Alzheimer Plan Memory Centers (4) 1459–1471

Mahringer, C., see Struhal, W. (2) 657–667

Maier, W., see Gomm, W. (2) 801–808

Maier, W., see Heser, K. (1) 185–199

Maier, W., see Wolfsgruber, S. (3) 1135–1146

Makarov, A.A., see Khmeleva, S.A. (2) 809–819

Makarov, A.A., see Morozov, A.V. (2) 763–776

Makino, K., see Makizako, H. (4) 1473–1482

Makizako, H., H. Shimada, T. Doi, K. Tsutsumimoto, R. Hotta, S. Nakakubo, K. Makino and T. Suzuki, Comorbid Mild Cognitive Impairment and Depressive Symptoms Predict Future Dementia in Community Older Adults: A 24-Month Follow-Up Longitudinal Study (4) 1473–1482

Malpas, C.B., L. Vivash, S. Genc, M.M. Saling, P. Desmond, C. Steward, R.J. Hicks, J. Callahan, A. Brodtmann, S. Collins, S. Macfarlane, N.M. Corcoran, C.M. Hovens, D. Velakoulis and T.J. O’Brien, A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer’s Disease (1) 223–232

Mamone, S., see Heser, K. (1) 185–199

Mancuso, L., see Gertje, E.C. (3) 1027–1037

Mandecka, M., M. Budziszewska, A. Barczak, B. Pepłońska, M. Chodakowska-Z?ebrowska, A. Fil-ipek-Gliszczyńska, M. Nesteruk, M. Styczyńska, M. Barcikowska and T. Gabryelewicz, Association between Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer’s Disease (1) 157–168

Mander, A., see Connors, M.H. (1) 149–155

Manousopoulou, A., see Portelius, E. (4) 1593–1605

Mapstone, M., see Ren, P. (1) 69–78

Maras, B., see Martire, S. (1) 307–324

Marchenkov, V.V., see Selivanova, O.M. (2) 821–830

Marchesi, N., M. Amadio, C. Colombrita, S. Govoni, A. Ratti and A. Pascale, PKC Activation Counteracts ADAM10 Deficit in HuD-Silenced Neuroblastoma Cells (2) 535–547

Maresova, P., B. Klimova, M. Novotny and K. Kuca, Alzheimer’s and Parkinson’s Diseases: Expected Economic Impact on Europe—A Call for a Uniform European Strategy (3) 1123–1133

Margolin, R.A., see Brody, M. (4) 1509–1519

Mari, D., see Arosio, B. (2) 417–425

Martin, C.K., see Myers, C.A. (4) 1359–1364

Martin, J.-J., see Somers, C. (1) 383–395

Martinez, A., see Santamaría-García, H. (3) 957–970

Martínez-Martínez, L., see Calderón-Garcidueñas, L. (2) 597–613

Martire, S., A. Fuso, L. Mosca, E. Forte, V. Correani, M. Fontana, S. Scarpa, B. Maras and M. d’Erme, Bioenergetic Impairment in Animal and Cellular Models of Alzheimer’s Disease: PARP-1 Inhibition Rescues Metabolic Dysfunctions (1) 307–324

Marugan, J., see Estrada, L.D. (3) 1193–1205

Matallana, D., see Santamaría-García, H. (3) 957–970

Matsumoto, S., see Hara, H. (3) 1047–1059

Matsunaga, S., T. Kishi and N. Iwata, Yokukansan in the Treatment of Behavioral and Psychological Symptoms of Dementia: An Updated Meta-Analysis of Randomized Controlled Trials (2) 635–643

Mäurer, A., see Ritter, K. (4) 1319–1331

Mazzeo, S., R. Santangelo, M.P. Bernasconi, G. Cecchetti, A. Fiorino, P. Pinto, G. Passerini, M. Falautano, G. Comi and G. Magnani, Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer’s Disease Dementia (4) 1495–1508

McAndrews, M.P., see Lozano, A.M. (2) 777–787

McClure, L.A., see Cushman, M. (2) 497–503

McCully, K.S., Homocysteine, Infections, Polyamines, Oxidative Metabolism, and the Pathogenesis of Dementia and Atherosclerosis (4) 1283–1290

McGeer, E.G., see McGeer, P.L. (3) 853–857

McGeer, P.L., J. Rogers and E.G. McGeer, Inflammation, Antiinflammatory Agents, and Alzheimer’s Disease: The Last 22 Years (3) 853–857

Mead, E., D. Kestoras, Y. Gibson, L. Hamilton, R. Goodson, S. Jones, S. Eversden, P. Davies, M. O’Neill, M. Hutton, P. Szekeres and J. Wolak, Halting of Caspase Activity Protects Tau from MC1-Conformational Change and Aggregation (4) 1521–1538

Mechanic-Hamilton, D., see Roalf, D.R. (1) 325–335

Meditskos, G., see Lazarou, I. (4) 1561–1591

Meijer, L., see Portelius, E. (4) 1593–1605

Mende, C., see Ritter, K. (4) 1319–1331

Mesulam, M.-M., see Guo, L. (3) 1157–1167

Meurs, E.F., see Gourmaud, S. (4) 1659–1670

Mezentsev, Y.V., see Khmeleva, S.A. (2) 809–819

Miceli, C., see Luccarini, I. (2) 737–750

Michaelson, D.M., see Boehm-Cagan, A. (3) 1219–1233

Middelstädt, J., A.-K. Folkerts, S. Blawath and E. Kalbe, Cognitive Stimulation for People with Dementia in Long-Term Care Facilities: Baseline Cognitive Level Predicts Cognitive Gains, Moderated by Depression (1) 253–268

Midorikawa, A., C.E. Leyton, D. Foxe, R. Landin-Romero, J.R. Hodges and O. Piguet, All Is Not Lost: Positive Behaviors in Alzheimer’s Disease and Behavioral-Variant Frontotemporal Dementia with Disease Severity (2) 549–558

Mikus, M., see Musunuri, S. (4) 1671–1686

Mintzer, J.E., see Rosenberg, P.B. (1) 373–381

Mirzaa, A., A. King, C. Troakes and C. Exley, The Identification of Aluminum in Human Brain Tissue Using Lumogallion and Fluorescence Microscopy (4) 1333–1338

Mitkevich, V.A., see Khmeleva, S.A. (2) 809–819

Mitkevich, V.A., see Morozov, A.V. (2) 763–776

Moberg, P.J., see Roalf, D.R. (1) 325–335

Mok, V.C.T., see Lou, W. (1) 397–409

Mollenhauer, B., see van Steenoven, I. (1) 287–295

Montalván, A., see Villarreal, A.E. (3) 897–901

Montañés, M., see Pérez-Grijalba, V. (2) 751–762

Montembeault, M., see Chapleau, M. (3) 941–955

Moos, T., see Zakarias, J.K. (3) 1183–1192

Morbelli, S., see Chincarini, A. (4) 1437–1457

Morgan, B.P., see Hakobyan, S. (2) 707–716

Mori, T., see Yoshino, Y. (4) 1349–1357

Morley, J.E., see Farr, S.A. (4) 1339–1348

Morozov, A.V., A.A. Kulikova, T.M. Astakhova, V.A. Mitkevich, K.M. Burnysheva, A.A. Adzhubei, P.A. Erokhov, M.B. Evgen’ev, N.P. Sharova, V.L. Karpov and A.A. Makarov, Amy-loid- ι ι ι Increases Activity of Proteasomes Capped with 19S and 11S Regulators (2) 763–776

Mörtl, C., see Struhal, W. (2) 657–667

Mosca, L., see Martire, S. (1) 307–324

Mösch, E., see Wolfsgruber, S. (3) 1135–1146

Mouton-Liger, F., see Gourmaud, S. (4) 1659–1670

Mouton-Liger, F., see Magnin, E. (4) 1459–1471

Muck, S., see Klafki, H.-W. (2) 691–705

Mueller, K.D., R.L. Koscik, L.S. Turkstra, S.K. Riedeman, A. LaRue, L.R. Clark, B. Hermann, M.A. Sager and S.C. Johnson, Connected Language in Late Middle-Aged Adults at Risk for Alzheimer’s Disease (4) 1539–1550

Mueller, K.D., see Racine, A.M. (4) 1395–1408

Mukhamedyarov, M.A., A.A. Rizvanov, E.Z. Yakupov, A.L. Zefirov, A.P. Kiyasov, H.J. Reis, A.L. Teixeira, L.B. Vieira, L.M. Lima, I.I. Salafutdinov, E.O. Petukhova, S.F. Khaiboullina, K.A. Schlauch, V.C. Lombardi and A. Palotás, Transcriptional Analysis of Blood Lymphocytes and Skin Fibroblasts, Keratinocytes, and Endothelial Cells as a Potential Biomarker for Alzheimer’s Disease (4) 1373–1383

Mukherjee, P.S., see Calderón-Garcidueñas, L. (2) 597–613

Mummery, C.J., see Westona, P.S.J. (4) 1297–1302

Munro, C., see Lozano, A.M. (2) 777–787

Musa, G., see Bertoux, M. (3) 1005–1014

Musunuri, S., P.E. Khoonsari, M. Mikus, M. Wetterhall, A. Häggmark-Månberg, L. Lannfelt, A. Erlandsson, J. Bergquist, M. Ingelsson, G. Shevchenko, P. Nilsson and K. Kultima, Increased Levels of Extracellular Microvesicle Markers and Decreased Levels of Endocytic/Exocytic Proteins in the Alzheimer’s Disease Brain (4) 1671–1686

Myers, C.A., J.N. Keller, H.R. Allen, R.M. Brouillette, H. Foil, A.B. Davis, F.L. Greenway, W.D. Johnson and C.K. Martin, Reliability and Validity of a Novel Internet-Based Battery to Assess Mood and Cognitive Function in the Elderly (4) 1359–1364

Na, D.L., see Noh, Y. (3) 1015–1026

Nagaraja, H.N., see Scharre, D.W. (3) 995–1004

Nagele, R.G., see Goldwaser, E.L. (2) 445–456

Nakakubo, S., see Makizako, H. (4) 1473–1482

Nakamura, S., see Hara, H. (3) 1047–1059

Nardiello, P., see Luccarini, I. (2) 737–750

Nascimento, C.F., see Grinberg, L.T. (1) 169–174

Naslavsky, M.S., see Grinberg, L.T. (1) 169–174

Nediani, C., see Luccarini, I. (2) 737–750

Nesteruk, M., see Mandecka, M. (1) 157–168

Nicholas, C.R., see Racine, A.M. (4) 1395–1408

Niehoff, M.L., see Farr, S.A. (4) 1339–1348

Nielsen, T.R., see Stevnsborg, L. (2) 505–514

Niemantsverdriet, E., see Somers, C. (1) 383–395

Nilsson, P., see Musunuri, S. (4) 1671–1686

Nitrini, R., see Grinberg, L.T. (1) 169–174

Nobili, F., see Bonanni, L. (4) 1649–1657

Nobili, F., see Chincarini, A. (4) 1437–1457

Noh, Y., S.W. Seo, S. Jeon, J.M. Lee, J.S. Kim,

J.-H. Lee, J.-H. Kim, G.H. Kim, B.S. Ye, H. Cho, H.J. Kim, C.W. Yoon, Y.S. Choe, K.-H. Lee, M.W. Weiner and D.L. Na, The Role of Cerebrovascular Disease in Amyloid Deposition (3) 1015–1026

Nørgaard, A., see Zakarias, J.K. (3) 1183–1192

Norton, D., see Racine, A.M. (4) 1395–1408

Novak, G., see Brody, M. (4) 1509–1519

Novak, M., see Zimova, I. (2) 831–843

Novotny, M., see Maresova, P. (3) 1123–1133

Núñez, L., see Calvo-Rodríguez, M. (1) 207–221

O’ Hara, R., see Durazzo, T.C. (1) 99–107

O’Brien, T.J., see Malpas, C.B. (1) 223–232

O’Bryant, S.E., see Johnson, L.A. (1) 201–206

O’Bryant, S.E., see Villarreal, A.E. (3) 897–901

O’Neill, M., see Mead, E. (4) 1521–1538

Oh, E., see Lozano, A.M. (2) 777–787

Okun, M.S., see Lozano, A.M. (2) 777–787

Olsen, I., and S.K. Singhrao, Inflammasome Involvement in Alzheimer’s Disease (1) 45–53

Olsson, L., see Tiiman, A. (3) 971–982

Omori, C., see Portelius, E. (4) 1593–1605

Onesti, E., see Trebbastoni, A. (3) 1039–1045

Ong, Y.-T., see Liu, S. (2) 585–595

Ono, F., see Hara, H. (3) 1047–1059

Onofrj, M., see Bonanni, L. (4) 1649–1657

Ordoñez-Gutierrez, L., I. Fernandez-Perez, J.L. Herrera, M. Anton, I. Benito-Cuesta and F. Wandosell, A ι ι ι PP/PS1 Transgenic Mice Show Sex Differences in the Cerebellum Associated with Aging (2) 645–656

Oumata, N., see Portelius, E. (4) 1593–1605

Ozaki, Y., see Yoshino, Y. (4) 1349–1357

Padovani, A., see Chincarini, A. (4) 1437–1457

Pallas, M., see Ettcheto, M. (1) 233–251

Palmeira, A., see López-González, I. (2) 471–475

Palotás, A., see Mukhamedyarov, M.A. (4) 1373–1383

Pannee, J., see Portelius, E. (4) 1593–1605

Pant, H.C., see Binukumar, B.K. (2) 525–533

Pantano, D., see Luccarini, I. (2) 737–750

Paquet, C., see Gourmaud, S. (4) 1659–1670

Paquet, C., see Magnin, E. (4) 1459–1471

Parham, C.L., C. Shaw, L.D. Auckland, S.K. Dickeson, I. Griswold-Prenner and G. Bix, Perlecan Domain V Inhibits Amyloid-b Induced Activation of the a2b1 Integrin-Mediated Neurotoxic Signaling Cascade (4) 1629–1647

Park, A., see Scharre, D.W. (3) 995–1004

Park, S.H., see Seo, E.H. (2) 559–568

Parkington, H.C., see Kuruppu, S. (3) 891–895

Parnetti, L., see Chiasserini, D. (1) 55–67

Pascale, A., see Marchesi, N. (2) 535–547

Pasinetti, G.M., see Varghese, M. (2) 477–496

Pasqualucci, C.A., see Grinberg, L.T. (1) 169–174

Pasquier, F., see Magnin, E. (4) 1459–1471

Passerini, G., see Mazzeo, S. (4) 1495–1508

Paterson, R.W., see Westona, P.S.J. (4) 1297–1302

Paxinos, G., see Fu, Y.H. (2) 569–584

Pedrós, I., see Ettcheto, M. (1) 233–251

Pelech, S.L., see Binukumar, B.K. (2) 525–533

Pellegrino, G., see Tombini, M. (4) 1619-1627

Pelleieux, S., see De Beaumont, L. (3) 913–922

Pendergrass, J.C., see Lozano, A.M. (2) 777–787

Pentzek, M., see Heser, K. (1) 185–199

Pentzek, M., see Wolfsgruber, S. (3) 1135–1146

Pepłońska, B., see Mandecka, M. (1) 157–168

Pereira, M.G., see Lima, S. (3) 1113–1121

Pérez-Grijalba, V., N. Fandos, J. Canudas, D. Insua, D. Casabona, A.M. Lacosta, M. Mon-tañés, P. Pesini and M. Sarasa, Validation of Immunoassay-Based Tools for the Comprehensive Quantification of A ι ι ι 40 and A ι ι ι 42 Peptides in Plasma (2) 751–762

Pesini, P., see Pérez-Grijalba, V. (2) 751–762

Peters, L., see Hülsemann, M. (1) 79–88

Peters, O., see Ritter, K. (4) 1319–1331

Petniak, A., see Ułamek-Kozioł, M. (1) 113–121

Petrella, R.J., see Heath, M. (3) 923–931

Petrov, D., see Ettcheto, M. (1) 233–251

Petukhova, E.O., see Mukhamedyarov, M.A. (4) 1373–1383

Piguet, O., see Midorikawa, A. (2) 549–558

Pinto, P., see Mazzeo, S. (4) 1495–1508

Pluta, J., see Gertje, E.C. (3) 1027–1037

Pluta, R., see Ułamek-Kozioł, M. (1) 113–121

Poirier, J., see De Beaumont, L. (3) 913–922

Polanco, J.C., see Baker, S. (3) 1207–1217

Ponce, F.A., see Lozano, A.M. (2) 777–787

Porsteinsson, A., see Ren, P. (1) 69–78

Porsteinsson, A.P., see Rosenberg, P.B. (1) 373–381

Portelius, E., E. Durieu, M. Bodin, M. Cam, J. Pannee, C. Leuxe, A. Mabondzo, N. Oumata, H. Galons, J.Y. Lee, Y.-T. Chang, K. Stüber, P. Koch, G. Fontaine, M.-C. Potier, A. Manousopoulou, S.D. Garbis, A. Covaci, D. Van Dam, P. De Deyn, F. Karg, M. Flajolet, C. Omori, S. Hata, T. Suzuki, K. Blennow, H. Zetterberg and L. Meijer, Specific Triazine Herbicides Induce Amyloid-b42 Production (4) 1593–1605

Posselt, T., see Heser, K. (1) 185–199

Potier, M.-C., see Portelius, E. (4) 1593–1605

Prasad, V., see Ritter, K. (4) 1319–1331

Qiu, T., X. Luo, Z. Shen, P. Huang, X. Xu, J. Zhou, M. Zhang and for the Alzheimer’s Disease Neuroimaging Initiative, Disrupted Brain Network in Progressive Mild Cognitive Impairment Measured by Eigenvector Centrality Mapping is Linked to Cognition and Cerebrospinal Fluid Biomarkers (4) 1483–1493

Quarmley, M., see Roalf, D.R. (1) 325–335

Racine, A.M., L.R. Clark, S.E. Berman, R.L. Koscik, K.D. Mueller, D. Norton, C.R. Nicholas, K. Blennow H. Zet-terbergj, B. Jedynak, M. Bilgel, C.M. Carlsson, B.T. Christian, S. Asthana and S.C. Johnson, Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Bi-omarkers in People at Risk for Alzheimer’s Disease (4) 1395–1408

Radko, S.P., see Khmeleva, S.A. (2) 809–819

Raffo, A., see Curiel, R.E. (2) 793–799

Rahimipour, S., see Tiiman, A. (3) 971–982

Rai, N., R. Kumar, G.R. Desai, G. Venugopalan, S. Shekhar, P. Chatterjee, M. Tripathi, A.D. Upadhyay, S. Dwivedi, A.B. Dey and S. Dey, Relative Alterations in Blood-Based Levels of Sestrin in Alzheimer’s Disease and Mild Cognitive Impairment Patients (3) 1147–1155

Rajapakse, N.W., see Kuruppu, S. (3) 891–895

Raman, R., see Rosenberg, P.B. (1) 373–381

Ramanan, S., see Bertoux, M. (3) 1005–1014

Ramirez, M.J., see Bengoetxea, X. (3) 1085–1094

Ransmayr, G., see Struhal, W. (2) 657–667

Ratti, A., see Marchesi, N. (2) 535–547

Rei, L., see Chincarini, A. (4) 1437–1457

Reis, H.J., see Mukhamedyarov, M.A. (4) 1373–1383

Reis, J., see Calderón-Garcidueñas, L. (2) 597–613

Ren, P., R.Y. Lo, B.P. Chapman, M. Mapstone, A. Porsteinsson, F. Lin and the Alzheimer’s Disease Neuroimaging Initiative, Longitudinal Alteration of Intrinsic Brain Activity in the Striatum in Mild Cognitive Impairment (1) 69–78

Renard, D., A. Gabelle, C. Hirtz, C. Demattei, E. Thouvenot and S. Lehmann, Cerebrospinal Fluid Alz-heimer’s Disease Biomarkers in Isolated Supratentorial Cortical Superficial Siderosis (4) 1291–1295

Reñé-Ramírez, R., see Turró-Garriga, O. (4) 1551–1560

Reyes, P., see Santamaría-García, H. (3) 957–970

Rezvanian, A., see Guo, L. (3) 1157–1167

Riedel-Heller, S.G., see Heser, K. (1) 185–199

Riedel-Heller, S.G., see Wolfsgruber, S. (3) 1135–1146

Riedeman, S.K., see Mueller, K.D. (4) 1539–1550

Rinne, J., see Iso-Markku, P. (4) 1303–1317

Ritter, K., C. Lange, M. Weygandt, A. Mäurer, A. Roberts, M. Estrella, P. Suppa, L. Spies, V. Prasad, I. Steffen, I. Apostolova, D. Bittner, M. Gövercin, W. Brenner, C. Mende, O. Peters, J. Seybold, J.B. Fiebach, E. Steinhagen-Thiessen, H. Hampel, J.-D. Haynes and R. Buchert, Combination of Structural MRI and FDG-PET of the Brain Improves Diagnostic Accuracy in Newly Manifested Cognitive Impairment in Geriatric Inpatients (4) 1319–1331

Rizvanov, A.A., see Mukhamedyarov, M.A. (4) 1373–1383

Roalf, D.R., M. Quarmley, D. Mechanic-Hamilton, D.A. Wolk, S.E. Arnold, P.J. Moberg and for the Alz-heimer’s Disease Neuroimaging Initiative, Within-Individual Variability: An Index for Subtle Change in Neurocognition in Mild Cognitive Impairment (1) 325–335

Robert, P., see Magnin, E. (4) 1459–1471

Roberts, A., see Ritter, K. (4) 1319–1331

Rogers, J., see McGeer, P.L. (3) 853–857

Roos, P., see Tiiman, A. (3) 971–982

Roose, D., see Blockx, I. (2) 723–735

Rosado, M., see Curiel, R.E. (2) 793–799

Roselli, F., see Li, Y. (1) 135–148

Rosenberg, P.B., K.L. Lanctôt, N. Herrmann, J.E. Mintzer, A.P. Porsteinsson, X. Sun and R. Raman, Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer’s Disease (1) 373–381

Rosenberg, P.B., see Lozano, A.M. (2) 777–787

Rossi, P.D., see Arosio, B. (2) 417–425

Rossor, M.N., see Westona, P.S.J. (4) 1297–1302

Ruiz-Ramos, R., see Calderón-Garcidueñas, L. (2) 597–613

Sabbagh, M., see Lozano, A.M. (2) 777–787

Sager, M.A., see Mueller, K.D. (4) 1539–1550

Salafutdinov, I.I., see Mukhamedyarov, M.A. (4) 1373–1383

Saling, M.M., see Malpas, C.B. (1) 223–232

Salloway, S., see Lozano, A.M. (2) 777–787

Salvadori, N., see Chiasserini, D. (1) 55–67

Samarasinghe, K., see Wijesinghe, P. (4) 1607–1618

Sandoval, K.E., see Farr, S.A. (4) 1339–1348

Santacruz, J.M., see Santamaría-García, H. (3) 957–970

Santa-Maria, I., see Varghese, M. (2) 477–496

Santamaría-García, H., P. Reyes, A. García, S. Baéz, A. Martinez, J.M. Santacruz, A. Slachevsky, M. Sigman, D. Matallana and A. Ibañez, First Symptoms and Neurocognitive Correlates of Behavioral Variant Frontotemporal Dementia (3) 957–970

Santangelo, R., see Mazzeo, S. (4) 1495–1508

Sao, T., see Yoshino, Y. (4) 1349–1357

Sarasa, M., see Pérez-Grijalba, V. (2) 751–762

Sarazin, M., see Bertoux, M. (3) 1005–1014

Sarkar, A., see Goldwaser, E.L. (2) 445–456

Scarpa, S., see Martire, S. (1) 307–324

Scarpini, E., see Cioffi, S.M.G. (2) 717–721

Scharre, D.W., S.-I. Chang, H.N. Nagaraja, A. Park, A. Adeli, P. Agrawal, A. Kloos, D. Kegelmeyer, S. Linder, N. Fritz, S.K. Kostyk and M. Kataki, Paired Studies Comparing Clinical Profiles of Lewy Body Dementia with Alzheimer’s and Parkinson’s Diseases (3) 995–1004

Scherbaum, N., see Klafki, H.-W. (2) 691–705

Scherer, M., see Heser, K. (1) 185–199

Scherer, M., see Wolfsgruber, S. (3) 1135–1146

Schlauch, K.A., see Mukhamedyarov, M.A. (4) 1373–1383

Schmidt, C., see Karch, A. (4) 1385–1393

Schmitz, M., see Karch, A. (4) 1385–1393

Schott, J.M., see Westona, P.S.J. (4) 1297–1302

Schuchhardt, J., see Klafki, H.-W. (2) 691–705

Scortichini, V., see Arosio, B. (2) 417–425

Selivanova, O.M., A.K. Surin, V.V. Marchenkov, U.F. Dzhus, E.I. Grigorashvili, M.Y. Suvorina, A.V. Glyakina, N.V. Dovidchenko and O.V. Galzitskaya, The Mechanism Underlying Amyloid Polymorphism is Opened for Alzheimer’s Disease Amy-loid- ι ι ι Peptide (2) 821–830

Sensi, F., see Chincarini, A. (4) 1437–1457

Seo, E.H., H. Kim, K.H. Lee and I.H. Choo, Altered Executive Function in Pre-Mild Cognitive Impairment (3) 933–940

Seo, E.H., S.H. Kim, S.H. Park, S.-H. Kang, I.H. Choo and for the Alzheimer’s Disease Neuroimaging Initiative, Topographical APOE ɛ4 Genotype Influence on Cerebral Metabolism in the Continuum of Alzheimer’s Disease: Amyloid Burden Adjusted Analysis (2) 559–568

Seo, S.W., see Noh, Y. (3) 1015–1026

Sepe-Monti, M., N. Vanacore, L. Bartorelli, A. Tognetti, F. Giubilei and Savvy Caregiver Study Group, The Savvy Caregiver Program: A Probe Multicenter Randomized Controlled Pilot Trial in Caregivers of Patients Affected by Alzheimer’s Disease (3) 1235–1246

Serpente, M., see Cioffi, S.M.G. (2) 717–721

Seybold, J., see Ritter, K. (4) 1319–1331

Shadman, A., see Brody, M. (4) 1509–1519

Shankar, S.K., see Wijesinghe, P. (4) 1607–1618

Shankle, W.R., J. Hara, L.W. Barrentine and M.V. Curole, CerefolinNAC Therapy of Hyperhomocysteinemia Delays Cortical and White Matter Atrophy in Alzheimer’s Disease and Cerebrovascular Disease (3) 1073–1084

Sharova, N.P., see Morozov, A.V. (2) 763–776

Shaw, C., see Parham, C.L. (4) 1629–1647

Shaw, L.M., see Durazzo, T.C. (1) 99–107

Shekhar, S., see Rai, N. (3) 1147–1155

Shen, D., see Zhang, H. (3) 1095–1112

Shen, Z., see Qiu, T. (4) 1483–1493

Shevchenko, G., see Musunuri, S. (4) 1671–1686

Shi, F., see Zhang, H. (3) 1095–1112

Shi, L., see Lou, W. (1) 397–409

ShiDu Yan, S., see Yu, Q. (2) 679–690

Shimada, H., see Makizako, H. (4) 1473–1482

Sholts, S.B., see Tiiman, A. (3) 971–982

Shu, H., see Chen, G. (3) 983–993

Shu, H., see Yuan, B. (4) 1409–1423

Shukla, V., see Binukumar, B.K. (2) 525–533

Sicari, M., see Tombini, M. (4) 1619–1627

Sigman, M., see Santamaría-García, H. (3) 957–970

Sinakos, Z., see Tsolaki, M. (1) 129–133

Singhrao S.K., see Olsen, I. (1) 45–53

Skuntz, S., see Binukumar, B.K. (2) 525–533

Slachevsky, A., see Bertoux, M. (3) 1005–1014

Slachevsky, A., see Santamaría-García, H. (3) 957–970

Smith, A.I., see Kuruppu, S. (3) 891–895

Smith, G.S., see Lozano, A.M. (2) 777–787

Smolek, T., see Zimova, I. (2) 831–843

Somers, C., H. Struyfs, J. Goossens, E. Niemantsverdriet, J. Luyckx, N. De Roeck, E. De Roeck, B. De Vil, P. Cras, J.-J. Martin, P.-P. De Deyn, M. Bjerke and S. Engelborghs, A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease in Belgium (1) 383–395

Song, Y., see Li, Y. (1) 135–148

Soto, C., see Estrada, L.D. (3) 1193–1205

Spallazzi, M., see Cioffi, S.M.G. (2) 717–721

Spicer, A.J., see Kuruppu, S. (3) 891–895

Spies, L., see Ritter, K. (4) 1319–1331

Stavropoulos, T.G., see Lazarou, I. (4) 1561–1591

Stefani, M., see Luccarini, I. (2) 737–750

Steffen, I., see Ritter, K. (4) 1319–1331

Stein, J., see Heser, K. (1) 185–199

Stein, J., see Wolfsgruber, S. (3) 1135–1146

Steinbusch, H.W.M., see Wijesinghe, P. (4) 1607–1618

Steiner, J., see Binukumar, B.K. (2) 525–533

Steinhagen-Thiessen, E., see Ritter, K. (4) 1319–1331

Steinmann, S., see Wolfsgruber, S. (3) 1135–1146

Stevnsborg, L., C. Jensen-Dahm, T.R. Nielsen, C. Gasse and G. Waldemar, Inequalities in Access to Treatment and Care for Patients with Dementia and Immigrant Background: A Danish Nationwide Study (2) 505–514

Stevnsborg, L., see Zakarias, J.K. (3) 1183–1192

Steward, C., see Malpas, C.B. (1) 223–232

Stoops, E., see Chiasserini, D. (1) 55–67

Struhal, W., C. Mahringer, H. Lahrmann, C. Mörtl, P. Buhl, M. Huemer and G. Ransmayr, Heart Rate Spectra Confirm the Presence of Autonomic Dysfunction in Dementia Patients (2) 657–667

Struyfs, H., see Somers, C. (1) 383–395

Stüber, K., see Portelius, E. (4) 1593–1605

Styczyńska, M., see Mandecka, M. (1) 157–168

Su, J., see Li, D. (1) 89–98

Suh, Y.-H., see Kang, J.M. (3) 879–889

Suh, Y.-h., see Wijesinghe, P. (4) 1607–1618

Sun, H., see Sun, J. (1) 175–184

Sun, J., R. Cai, R. Huang, P. Wang, S. Tian, H. Sun, W. Xia and S. Wang, Cholesteryl Ester Transfer Protein Inti-mately Involved in Dyslipidemia-Related Susceptibility to Cognitive Deficits in Type 2 Diabetic Patients (1) 175–184

Sun, X., see Rosenberg, P.B. (1) 373–381

Suppa, P., see Ritter, K. (4) 1319–1331

Surin, A.K., see Selivanova, O.M. (2) 821–830

Sutter, C., see Binukumar, B.K. (2) 525–533

Suvorina, M.Y., see Selivanova, O.M. (2) 821–830

Suzuki, T., see Makizako, H. (4) 1473–1482

Suzuki, T., see Portelius, E. (4) 1593–1605

Swerdlow, R.H., see Yu, Q. (2) 679–690

Szekeres, P., see Mead, E. (4) 1521–1538

Tabira, T., see Hara, H. (3) 1047–1059

Taheri, S., J. Yu, H. Zhu and M.S. Kindy, High-Sodium Diet Has Opposing Effects on Mean Arterial Blood Pressure and Cerebral Perfusion in a Transgenic Mouse Model of Alzheimer’s Disease (3) 1061–1072

Takada, L.T., see Grinberg, L.T. (1) 169–174

Tales, A., see Jenkins, A. (3) 1169–1182

Tan, E.C.K., J.S. Bell, C.Y. Lu and S. Toh, National Trends in Outpatient Antihypertensive Prescribing in People with Dementia in the United States (4) 1425–1435

Tang-Wai, D.F., see Lozano, A.M. (2) 777–787

Targum, S.D., see Lozano, A.M. (2) 777–787

Taylor, J.-P., see Bonanni, L. (4) 1649–1657

Teixeira, A.L., see Mukhamedyarov, M.A. (4) 1373–1383

Teunissen, C.E., see van Steenoven, I. (1) 287–295

Thacker, E.L., see Cushman, M. (2) 497–503

Thomé, F., see Gomm, W. (2) 801–808

Thompson, C., see Calderón-Garcidueñas, L. (2) 597–613

Thornton, I.M., see Jenkins, A. (3) 1169–1182

Thouvenot, E., see Renard, D. (4) 1291–1295

Tian, S., see Sun, J. (1) 175–184

Tierney, M.C., see Jaakkimainen, R.L. (1) 337–349

Tiiman, A., J. Luo, C. Wallin, L. Olsson, J. Lindgren, J. Jarvet, P. Roos, S.B. Sholts, S. Rahimipour, J.P. Abrahams, A.E. Karlström, A. Gräslund and S.K.T.S. Wärmländer, Specific Binding of Cu(II) Ions to Amyloid-Beta Peptides Bound to Aggregation-Inhibiting Molecules or SDS Micelles Creates Complexes that Generate Radical Oxygen Species (3) 971–982

Tio, G., see Magnin, E. (4) 1459–1471

Tognetti, A., see Sepe-Monti, M. (3) 1235–1246

Toh, S., see Tan, E.C.K. (4) 1425–1435

Tombini, M., M. Sicari, G. Pellegrino, F. Ursini, P. Insardá and V. Di Lazzaro, Nutritional Status of Patients with Alzheimer’s Disease and Their Caregivers (4) 1619–1627

Torres-Jardón, R., see Calderón-Garcidueñas, L. (2) 597–613

Trebbastoni, A., F. D’Antonio, C. de Lena, E. Onesti, B. John and M. Inghilleri, Primary Progressive Orofacial Apraxia: A Ten-Year Long Follow-Up Case Report (3) 1039–1045

Tripathi, M., see Rai, N. (3) 1147–1155

Troakes, C., see Mirzaa, A. (4) 1333–1338

Trojanowski, J.Q., see Durazzo, T.C. (1) 99–107

Troussière, A.-C., see Magnin, E. (4) 1459–1471

Trumbore, C.N., Shear-Induced Amyloid Formation in the Brain: I. Potential Vascular and Parenc hymal Processes (2) 457–470

Tsolaki, A., see Tsolaki, M. (1) 129–133

Tsolaki, M., E. Karathanasi, I. Lazarou, K. Dovas, E. Verykouki, A. Karakostas, K. Georgiadis, A. Tsolaki, K. Adam, I. Kompatsiaris and Z. Sinakos, Efficacy and Safety of Crocus sativus L. in Patients with Mild Cognitive Impairment: One Year Single-Blind Randomized, with Parallel Groups, Clinical Trial (1) 129–133

Tsolaki, M., see Lazarou, I. (4) 1561–1591

Tsompanidis, T., see Lazarou, I. (4) 1561–1591

Tsoy, E., see Levy, B. (4) 1259–1272

Tsutsumimoto, K., see Makizako, H. (4) 1473–1482

Tu, K., see Jaakkimainen, R.L. (1) 337–349

Turkstra, L.S., see Mueller, K.D. (4) 1539–1550

Turró-Garriga, O., J. Garre-Olmo, R. Reñé-Ramírez, L. Calvó-Perxas, J. Gascón-Bayarri and J.-L. Conde-Sala, Consequences of Anosognosia on the Cost of Caregivers’ Care in Alzheimer’s Disease (4) 1551–1560

Ueno, S.-i., see Yoshino, Y. (4) 1349–1357

Ułamek-Kozioł, M., J. Kocki, A. Bogucka-Kocka, A. Petniak, P. Gil-Kulik, S. Januszewski, J. Bogucki, M. Jabłoński, W. Furmaga-Jabłońska, J. Brzozowska, S.J. Czuczwar and R. Pluta, Dysregulation of Autophagy, Mitophagy, and Apoptotic Genes in the Medial Temporal Lobe Cortex in an Ischemic Model of Alzheimer’s Disease (1) 113–121

Unverzagt, F.W., see Cushman, M. (2) 497–503

Upadhyay, A.D., see Rai, N. (3) 1147–1155

Ursini, F., see Tombini, M. (4) 1619–1627

Valachova, B., see Zimova, I. (2) 831–843

Van Dam, D., see Portelius, E. (4) 1593–1605

van der Flier, W.M., see van Steenoven, I. (1) 287–295

Van der Linden, A., see Blockx, I. (2) 723–735

van Steenoven, I., D. Aarsland, D. Weintraub, E. Londos, F. Blanc, W.M. van der Flier, C.E. Teunissen, B. Mollenhauer, T. Fladby, M.G. Kramberger, L. Bonanni, A.W. Lemstra and on behalf of the EuropeanDLB consortium, Cerebrospinal Fluid Alzheimer’s Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort (1) 287–295

Vanacore, N., see Sepe-Monti, M. (3) 1235–1246

Vanderstichele, H., see Chiasserini, D. (1) 55–67

Varghese, M., I. Santa-Maria, L. Ho, L. Ward, S. Yemul, L. Dubner, H. Ksie?z?ak-Reding and G.M. Pasinetti, Extracellular Tau Paired Helical Filaments Differentially Affect Tau Pathogenic Mechanisms in Mitotic and Post-Mitotic Cells: Implications for Mechanisms of Tau Propagation in the Brain (2) 477–496

Velakoulis, D., see Malpas, C.B. (1) 223–232

Venugopalan, G., see Rai, N. (3) 1147–1155

Verhoye, M., see Blockx, I. (2) 723–735

Verykouki, E., see Tsolaki, M. (1) 129–133

Vieira, L.B., see Mukhamedyarov, M.A. (4) 1373–1383

Vijayan, M. and P. Hemachandra Reddy, Stroke, Vascular Dementia, and Alzheimer’s Disease: Molecular Links (2) 427–443

Villalobos, C., see Calvo-Rodríguez, M. (1) 207–221

Villarreal, A.E., S. Grajales, S.E. O’Bryant, M. Edwards, L. López, A. Montalván and G.B. Britton for the Panama Aging Research Initiative (PARI), Characterization of Alzheimer’s Disease and Mild Cognitive Impairment in Older Adults in Panama (3) 897–901

Vintimilla, R., see Johnson, L.A. (1) 201–206

Vivash, L., see Malpas, C.B. (1) 223–232

Volpe-Gillot, L., see Magnin, E. (4) 1459–1471

von Bernhardi, R., see Estrada, L.D. (3) 1193–1205

von Holt, K., see Gomm, W. (2) 801–808

Vuoksimaa, E., see Iso-Markku, P. (4) 1303–1317

Wadley, V.G., see Cushman, M. (2) 497–503

Wagner, M., see Heser, K. (1) 185–199

Wagner, M., see Wolfsgruber, S. (3) 1135–1146

Waldemar, G., see Stevnsborg, L. (2) 505–514

Waldemar, G., see Zakarias, J.K. (3) 1183–1192

Waldorff, F.B., see Zakarias, J.K. (3) 1183–1192

Waller, K., see Iso-Markku, P. (4) 1303–1317

Wallin, C., see Tiiman, A. (3) 971–982

Wallon, D., see Magnin, E. (4) 1459–1471

Wandosell, F., see Ordoñez-Gutierrez, L. (2) 645–656

Wang, D., see Lou, W. (1) 397–409

Wang, H., Y. Wang, X. Hong, S. Li and Y. Wang, Quantitative Proteomics Reveals the Mechanism of Oxygen Treatment on Lenses of Alzheimer’s Disease Model Mice (1) 275–286

Wang, P., K. Chen, L. Yao, B. Hu, X. Wu, J. Zhang, Q. Ye and X. Guo, for the Alzheimer’s Disease Neu-roimaging Initiative, Multimodal Classification of Mild Cognitive Impairment Based on Partial Least Squares (1) 359–371

Wang, P., see Sun, J. (1) 175–184

Wang, S., see Sun, J. (1) 175–184

Wang, W., see Yu, L. (1) 297–306

Wang, Y., see Wang, H. (1) 275–286

Wang, Y., see Wang, H. (1) 275–286

Wang, Z., see Yuan, B. (4) 1409–1423

Ward, B.D., see Chen, G. (3) 983–993

Ward, J., see Connors, M.H. (1) 149–155

Ward, L., see Varghese, M. (2) 477–496

Wärmländer, S.K.T.S., see Tiiman, A. (3) 971–982

Warren, J.D., see Westona, P.S.J. (4) 1297–1302

Weckbecker, K., see Gomm, W. (2) 801–808

Weeg, D., see Heser, K. (1) 185–199

Weiler, J., see Heath, M. (3) 923–931

Weiner, M.W., see Durazzo, T.C. (1) 99–107

Weiner, M.W., see Noh, Y. (3) 1015–1026

Weintraub, D., see van Steenoven, I. (1) 287–295

Weiser, B., see Johnson, L.A. (1) 201–206

Weisova, P., see Zimova, I. (2) 831–843

Werle, J., see Heser, K. (1) 185–199

Werle, J., see Wolfsgruber, S. (3) 1135–1146

Werth, J.L., see Brody, M. (4) 1509–1519

Westona, P.S.J., R.W. Paterson, J. Dickson, A. Barnes, J.B. Bomanji, I. Kayani, M.P. Lunn, C.J. Mummery, J.D. Warren, M.N. Rossor, N.C. Fox, H. Zetterberg and J.M. Schott, Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid? (4) 1297–1302

Wetterhall, M., see Musunuri, S. (4) 1671–1686

Weyerer, S., see Heser, K. (1) 185–199

Weyerer, S., see Wolfsgruber, S. (3) 1135–1146

Weygandt, M., see Ritter, K. (4) 1319–1331

Widdifield, J., see Jaakkimainen, R.L. (1) 337–349

Wiese, B., see Heser, K. (1) 185–199

Wiese, B., see Wolfsgruber, S. (3) 1135–1146

Wijesinghe, P., S.K. Shankar, T.C. Yasha, C. Gorrie, D. Amaratunga, S. Hulathduwa, K.S. Kumara, K. Samara-singhe, Y.-h. Suh, H.W.M. Steinbusch and K.R.D. De Silva, Vascular Contributions in Alzheimer’s Disease-Related Neuropathological Changes: First Autopsy Evidence from a South Asian Aging Population (4) 1607–1618

Willbold, D., see Hülsemann, M. (1) 79–88

Willbold, J., see Hülsemann, M. (1) 79–88

Willbold, S., see Hülsemann, M. (1) 79–88

Willich, S.N., see Brüuggenjürgen, B. (4) 1365–1372

Wiltfang, J., see Klafki, H.-W. (2) 691–705

Witt, K.A., see Farr, S.A. (4) 1339–1348

Wolak, J., see Mead, E. (4) 1521–1538

Wolfsgruber, S., L. Kleineidam, M. Wagner, E. Mösch, H. Bickel, D. Lühmann, A. Ernst, B. Wiese, S. Steinmann, H.-H. König, C. Brettschneider, T. Luck, J. Stein, S. Weyerer, J. Werle, M. Pentzek, A. Fuchs, W. Maier, M. Scherer, S.G. Riedel-Heller, F. Jessen and for the AgeCoDe Study Group, Differential Risk of Incident Alzheimer’s Disease Dementia in Stable Versus Unstable Patterns of Subjective Cognitive Decline (3) 1135–1146

Wolk, D., see Gertje, E.C. (3) 1027–1037

Wolk, D.A., see Lozano, A.M. (2) 777–787

Wolk, D.A., see Roalf, D.R. (1) 325–335

Wong, A., see Lou, W. (1) 397–409

Wong, S., see Bertoux, M. (3) 1005–1014

Wong, T.Y., see Liu, S. (2) 585–595

Woodward, M., see Connors, M.H. (1) 149–155

Wu, X., see Wang, P. (1) 359–371

Wu, Y., see Li, Y. (1) 135–148

Xia, W., see Sun, J. (1) 175–184

Xiao, Z., see Yu, L. (1) 297–306

Xie, C., see Yuan, B. (4) 1409–1423

Xu, X., see Qiu, T. (4) 1483–1493

Yadav, M., see Johnson, L.A. (1) 201–206

Yakupov, E.Z., see Mukhamedyarov, M.A. (4) 1373–1383

Yamazaki, K., see Yoshino, Y. (4) 1349–1357

Yañez, M.J., see Estrada, L.D. (3) 1193–1205

Yang, Y.-H., see Ho, B.-L. (1) 351–357

Yao, L., see Wang, P. (1) 359–371

Yasha, T.C., see Wijesinghe, P. (4) 1607–1618

Ye, B.S., see Noh, Y. (3) 1015–1026

Ye, Q., see Wang, P. (1) 359–371

Yemul, S., see Varghese, M. (2) 477–496

Yeon, B.K., see Kang, J.M. (3) 879–889

Yoon, C.W., see Noh, Y. (3) 1015–1026

Yoshida, T., see Yoshino, Y. (4) 1349–1357

Yoshino, Y., T. Mori, T. Yoshida, K. Yamazaki, Y. Ozaki, T. Sao, Y. Funahashi, J.-i. Iga and S.-i. Ueno, Elevated mRNA Expression and Low Methylation of SNCA in Japanese Alzheimer’s Disease Subjects (4) 1349–1357

Young, J., see Jaakkimainen, R.L. (1) 337–349

Yu, H., see Yu, Q. (2) 679–690

Yu, J., see Taheri, S. (3) 1061–1072

Yu, L., Y. Chen, W. Wang, Z. Xiao and Y. Hong, Multi-Vitamin B Supplementation Reverses Hypoxia-Induced Tau Hyperphosphorylation and Improves Memory Function in Adult Mice (1) 297–306

Yu, Q., D. Fang, R.H. Swerdlow, H. Yu, J.X. Chen and S. ShiDu Yan, Antioxidants Rescue Mitochondrial Transport in Differentiated Alzheimer’s Disease Trans-Mitochondrial Cybrid Cells (2) 679–690

Yuan, B., C. Xie, H. Shu, W. Liao, Z. Wang, D. Liu and Z. Zhang, Differential Effects of APOE Genotypes on the Anterior and Posterior Subnetworks of Default Mode Network in Amnestic Mild Cognitive Impairment (4) 1409–1423

Yushkevich, P., see Gertje, E.C. (3) 1027–1037

Zafar, S., see Karch, A. (4) 1385–1393

Zafiu, C., see Hülsemann, M. (1) 79–88

Zago, W., see Blockx, I. (2) 723–735

Zakarias, J.K., C. Jensen-Dahm, A. Nørgaard, L. Stevnsborg, C. Gasse, B.G. Andersen, S. Jakobsen, F.B. Waldorff, T. Moos and G. Waldemar, Geographical Variation in Antipsychotic Drug Use in Elderly Patients with Dementia: A Nationwide Study (3) 1183–1192

Zanlungo, S., see Estrada, L.D. (3) 1193–1205

Zefirov, A.L., see Mukhamedyarov, M.A. (4) 1373–1383

Zerr, I., see Karch, A. (4) 1385–1393

Zetterberg, H., see Portelius, E. (4) 1593–1605

Zetterberg, H., see Racine, A.M. (4) 1395–1408

Zetterberg, H., see Westona, P.S.J. (4) 1297–1302

Zhang, H., X. Chen, F. Shi, G. Li, M. Kim, P. Giannakopoulos, S. Haller and D. Shen, Topographical Infor-mation-Based High-Order Functional Connectivity and Its Application in Abnormality Detection for Mild Cognitive Impairment (3) 1095–1112

Zhang, J., see Wang, P. (1) 359–371

Zhang, M., see Qiu, T. (4) 1483–1493

Zhang, Y.-X., see Li, D. (1) 89–98

Zhang, Z., see Chen, G. (3) 983–993

Zhang, Z., see Yuan, B. (4) 1409–1423

Zhou, J., see Liu, S. (2) 585–595

Zhou, J., see Qiu, T. (4) 1483–1493

Zhou, W., see Li, Y. (1) 135–148

Zhou, W.-X., see Li, D. (1) 89–98

Zhou, X., see Beckelman, B.C. (2) 669–678

Zhu, H., see Taheri, S. (3) 1061–1072

Zilka, N., see Zimova, I. (2) 831–843

Zimova, I., V. Brezovakova, T. Hromadka, P. Weisova, V. Cubinkova, B. Valachova, P. Filipcik, S. Jadhav, T. Smolek, M. Novak and N. Zilka, Human Truncated Tau Induces Mature Neurofibrillary Pathology in a Mouse Model of Human Tauopathy (2) 831–843